Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
39.7 /100
Rank 54 out of 131 Industries -
Advance/Decline
170/169
-
No. of Companies339
-
Avg. Market Cap15,027
-
Price to Earning Ratio4.82
-
Price to Earning Growth Ratio1.73
-
Price to Book Ratio21.47
-
Return on Equity12.31
-
Return on Capital Employed-
-
Return on Assets7.27
-
Dividend yield 1 year %0.66 %
-
Net Profit Growth Annual YoY %-66.15 %
-
Net Profit Growth Qtr YoY %-17.90 %
-
Net Profit Growth Qtr QoQ %155.11 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
438,192.1
|
248.0
|
L
 0.8%
H
244.0
248.0
|
L
 -1.2%
H
241.2
256.2
|
L
 -0.8%
H
241.2
267.5
|
L
 23.0%
H
202.0
267.5
|
L
 25.2%
H
190.8
267.5
|
L
 64.5%
H
135.9
267.5
|
L
 117.4%
H
105.6
267.5
|
L
 271.4%
H
55.1
267.5
|
| Adc Therapeutics SA |
|
143.7
|
1.1
|
L
H
1.1
1.2
|
L
 7.6%
H
1.0
1.2
|
L
 -13.1%
H
1.0
1.5
|
L
 -67.7%
H
0.8
3.7
|
L
 -57.8%
H
0.8
5.0
|
L
 -24.7%
H
0.4
6.0
|
L
 -95.9%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
5,709.6
|
17.9
|
L
 -1.4%
H
17.7
18.2
|
L
 -2.4%
H
17.7
19.2
|
L
 5.1%
H
16.6
19.3
|
L
 35.5%
H
11.8
19.3
|
L
 109.4%
H
8.5
19.3
|
L
 322.7%
H
3.4
19.3
|
L
 247.9%
H
1.2
19.3
|
L
 -23.7%
H
1.2
27.3
|
| Annovis Bio Inc |
|
80.4
|
1.9
|
L
 0.5%
H
1.9
1.9
|
L
 8%
H
1.7
2.0
|
L
 -3.1%
H
1.6
2.0
|
L
 -17.1%
H
1.6
2.5
|
L
 -25.9%
H
1.5
5.5
|
L
 -85.5%
H
1.1
22.5
|
L
 -95.3%
H
1.1
43.4
|
L
H
1.1
132
|
| Bristol-Myers Squibb |
|
132,449.6
|
64.8
|
L
 0.2%
H
64.1
65.3
|
L
 -0.7%
H
63.2
68.1
|
L
 11.9%
H
56.8
68.1
|
L
 15.5%
H
53.4
68.1
|
L
 41.1%
H
42.5
68.1
|
L
 7.0%
H
39.4
68.1
|
L
 -3.8%
H
39.4
81.4
|
L
 5.2%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
229.2
|
4.5
|
L
 -7.6%
H
4.4
4.7
|
L
 -38.1%
H
4.4
7.7
|
L
 -45.4%
H
4.4
8.2
|
L
 -53.0%
H
4.4
9.7
|
L
 -47.8%
H
4.4
14.1
|
L
 -24.5%
H
1.4
15.1
|
L
 -92.7%
H
1.4
65.1
|
L
 -84.9%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
104,466.3
|
52.2
|
L
 -1.5%
H
51.5
52.2
|
L
 0.9%
H
50.9
53.1
|
L
 -0.6%
H
49.9
55.8
|
L
 3.5%
H
48.6
55.8
|
L
 38.0%
H
37.7
61.7
|
L
 48.3%
H
31.7
61.7
|
L
 26.3%
H
28.5
61.7
|
L
 15.4%
H
28.5
61.7
|
| Johnson & Johnson |
|
630,935.6
|
261.8
|
L
 1.0%
H
258.6
262
|
L
 2.1%
H
250.4
262.1
|
L
 1.1%
H
245.5
274.9
|
L
 18.3%
H
220.4
274.9
|
L
 51.1%
H
171.8
274.9
|
L
 51.3%
H
140.7
274.9
|
L
 50.7%
H
140.7
274.9
|
L
 112.1%
H
109.2
274.9
|
| Eli Lilly |
|
1,098,098.4
|
1,231.9
|
L
 3.9%
H
1184.4
1231.9
|
L
 7.2%
H
1109.2
1231.9
|
L
 1.2%
H
1109.2
1232
|
L
 29.9%
H
943.3
1249.5
|
L
 96.9%
H
625.9
1249.5
|
L
 134.1%
H
516.6
1249.5
|
L
 361.1%
H
220.2
1249.5
|
L
 1411.6%
H
64.2
1249.5
|
| Merck & Company |
|
323,349.4
|
130.9
|
L
 1.8%
H
128.2
131.0
|
L
 0.6%
H
126.2
131.5
|
L
 4.7%
H
120.2
135.1
|
L
 17.5%
H
110.9
135.1
|
L
 62.3%
H
77.6
135.1
|
L
 23.4%
H
73.3
135.1
|
L
 73.8%
H
70.9
135.1
|
L
 119.6%
H
50.4
135.1
|
| Novo Nordisk (ADR) |
|
211,002.4
|
47.7
|
L
 1.0%
H
46.7
47.7
|
L
 1.4%
H
43.7
49.2
|
L
 -2.4%
H
43.7
52.1
|
L
 3.6%
H
41
52.1
|
L
 -6.6%
H
35.1
64.2
|
L
 -49.1%
H
35.1
148.2
|
L
 -5.2%
H
35.1
148.2
|
L
 98.7%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
298,013.1
|
156.8
|
L
 0.3%
H
155.4
156.9
|
L
 0.4%
H
153.0
156.9
|
L
 1.4%
H
149.3
160.3
|
L
 7.4%
H
142.3
160.6
|
L
 34.2%
H
117.5
170.5
|
L
 51.7%
H
92.2
170.5
|
L
 70.8%
H
74.1
170.5
|
L
 114.6%
H
59.2
170.5
|
| Organon & Co. |
|
3,576.7
|
13.6
|
L
 0.2%
H
13.6
13.6
|
L
 0.5%
H
13.5
13.6
|
L
 1.0%
H
13.5
13.6
|
L
 2.2%
H
13.3
13.6
|
L
 47.7%
H
5.7
13.6
|
L
 -41.2%
H
5.7
24.0
|
L
 -53.2%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,510.7
|
53
|
L
 -3.4%
H
52.6
54.9
|
L
 5.5%
H
50.6
56.0
|
L
 9.3%
H
47.0
56.0
|
L
 0.9%
H
42.6
56.0
|
L
 -19.2%
H
42.6
71.1
|
L
 -18.5%
H
42.6
90.0
|
L
 -9.2%
H
42.6
90.0
|
L
 6.8%
H
26.3
90.0
|
| Pfizer |
|
154,176.2
|
27.1
|
L
 1.1%
H
26.5
27.2
|
L
 8.2%
H
24.7
27.2
|
L
 11.6%
H
24.1
27.2
|
L
 5.3%
H
23.6
27.2
|
L
 10.1%
H
23.6
28.7
|
L
 -24.5%
H
20.9
37.2
|
L
 -41.2%
H
20.9
61.7
|
L
 -18.6%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,754.0
|
12.6
|
L
 -1.6%
H
12.4
12.8
|
L
 25.0%
H
10.3
13.7
|
L
 21.4%
H
9.8
13.7
|
L
 7.9%
H
9.4
13.7
|
L
 -44.0%
H
9.2
24.6
|
L
 -67.5%
H
9.2
39.7
|
L
 -74.0%
H
9.2
50.9
|
L
 -86.7%
H
9.2
99.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
10,121.0
|
12.2
|
L
 -0.6%
H
11.6
12.3
|
L
 2.5%
H
11.6
12.3
|
L
 -12.5%
H
11.4
13.7
|
L
 -8.2%
H
11.4
15.7
|
L
 -12.0%
H
11.4
15.7
|
L
 -15.1%
H
11.4
74.9
|
L
 -5.7%
H
9.6
74.9
|
L
 35.2%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
56,046.0
|
17.6
|
L
 0.6%
H
17.4
17.6
|
L
 2.7%
H
16.3
17.6
|
L
 5.7%
H
16.2
17.8
|
L
 6.6%
H
14.8
17.8
|
L
 21.5%
H
13.0
18.9
|
L
 13.9%
H
12.6
18.9
|
L
 6.9%
H
12.3
18.9
|
L
 -24.9%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
42,113.8
|
36.1
|
L
 2.2%
H
35
36.1
|
L
 3.2%
H
33.8
36.1
|
L
 9.2%
H
29.6
36.1
|
L
 1.2%
H
29.6
36.4
|
L
 120.8%
H
16.3
37.3
|
L
 273.3%
H
8.1
37.3
|
L
 260.0%
H
6.8
37.3
|
L
 -32.4%
H
6.1
55.4
|
| Zoetis (Class A) |
|
30,921.5
|
74.8
|
L
 3.0%
H
71.5
75.0
|
L
 -3.2%
H
71.5
80.2
|
L
 -0.3%
H
71.5
80.2
|
L
 -9.7%
H
71.5
83.0
|
L
 -49.2%
H
71.5
160.5
|
L
 -60.5%
H
71.5
201.9
|
L
 -62.5%
H
71.5
249.3
|
L
 46.9%
H
46.9
249.3
|
| Biohaven Ltd |
|
2,189.2
|
14.5
|
L
 -0.8%
H
14.5
14.9
|
L
 7.7%
H
13.1
14.9
|
L
 -13.4%
H
13.1
16.4
|
L
 47.5%
H
8.2
17.3
|
L
 -1.4%
H
7.5
18.6
|
L
 -31.6%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Haleon PLC (ADR) |
|
43,730.4
|
9.9
|
L
 -1%
H
9.8
10.0
|
L
 0.6%
H
9.6
10.1
|
L
 2.3%
H
9.6
10.3
|
L
 9%
H
8.7
10.3
|
L
 4.1%
H
8.7
11.3
|
L
 17.1%
H
7.7
11.4
|
L
H
5.6
11.4
|
L
H
5.6
11.4
|
| Abeona Therapeutics Inc |
|
424.6
|
7.5
|
L
 2.9%
H
7.1
7.5
|
L
 16.0%
H
6.3
7.5
|
L
 4.6%
H
5.8
7.5
|
L
 26.3%
H
5.1
7.5
|
L
 19.0%
H
4
7.5
|
L
 148.3%
H
2.9
9.0
|
L
 -76.7%
H
2.2
34
|
L
 -92.2%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
6,341.2
|
105.1
|
L
 6.4%
H
95.5
105.3
|
L
 8.9%
H
90.6
105.3
|
L
 19.1%
H
80.7
105.3
|
L
 62.8%
H
53.6
105.3
|
L
 703.2%
H
12.8
105.3
|
L
 331.6%
H
2.2
105.3
|
L
 186.3%
H
2.2
105.3
|
L
 -84.0%
H
2.2
674.7
|
| Acumen Pharma Inc |
|
175.5
|
2.4
|
L
 -0.4%
H
2.4
2.5
|
L
 13.0%
H
2.1
2.5
|
L
 -10%
H
2.1
2.8
|
L
 -5.1%
H
2.1
2.8
|
L
 78.7%
H
1.2
3.6
|
L
 -64.2%
H
0.9
7.3
|
L
 -83.8%
H
0.9
19.5
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
906.7
|
4.6
|
L
 -0.9%
H
4.5
4.7
|
L
 5.8%
H
4.3
4.7
|
L
 -10.7%
H
4.3
5.2
|
L
 5.8%
H
4.1
5.4
|
L
 35%
H
3.3
5.4
|
L
 126.1%
H
1.7
5.4
|
L
 48.5%
H
1.7
6.5
|
L
 20.8%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
24.7
|
1.0
|
L
 -6.9%
H
0.9
1.0
|
L
 -5.9%
H
0.9
1.1
|
L
 -34.5%
H
0.9
1.6
|
L
 -10.4%
H
0.9
2.2
|
L
 -64.8%
H
0.9
3.4
|
L
 -60.1%
H
0.4
5.5
|
L
 -97.0%
H
0.4
116.9
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
5,064.1
|
29.4
|
L
 0.6%
H
29
29.7
|
L
 13.6%
H
25.4
29.7
|
L
 11.3%
H
24.2
29.7
|
L
 31.2%
H
20.3
29.7
|
L
 19.5%
H
19.7
29.7
|
L
 10.5%
H
13.4
32.6
|
L
 53.4%
H
12.2
33.9
|
L
 -11.8%
H
12.2
58.7
|
| Adicet Bio Inc |
|
75.9
|
8.1
|
L
 1.6%
H
7.9
8.2
|
L
 -11.0%
H
7.4
9.8
|
L
 -9.3%
H
7.4
9.8
|
L
 -5.2%
H
7.0
9.8
|
L
 -18.4%
H
6.0
17.4
|
L
 -75.9%
H
6.0
60.3
|
L
 -92.8%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
684.7
|
6.7
|
L
 0.3%
H
6.6
6.8
|
L
 3.9%
H
6.2
6.8
|
L
 4.2%
H
5.8
6.8
|
L
 28.0%
H
4.4
7.1
|
L
 166.8%
H
2.4
7.1
|
L
 25.4%
H
1.8
7.1
|
L
 -10.3%
H
1.8
10.3
|
L
 -99.7%
H
1.8
2057.2
|
| AC Immune SA |
|
232.0
|
2.3
|
L
 -3.4%
H
2.3
2.4
|
L
 4.1%
H
2.2
2.4
|
L
 -12.3%
H
2.1
2.6
|
L
 -20.3%
H
2.1
3.1
|
L
 6.5%
H
2.0
4
|
L
 -24.8%
H
1.4
5.1
|
L
 -68.2%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
867.1
|
5.9
|
L
 -0.2%
H
5.7
6.0
|
L
 13.5%
H
5.0
6.5
|
L
 3.3%
H
5.0
6.5
|
L
 19.7%
H
4.1
6.5
|
L
 262.0%
H
1.6
6.5
|
L
 -30.4%
H
0.6
8.7
|
L
 -59.6%
H
0.6
20.0
|
L
 -68.7%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
74.5
|
1.7
|
L
 0.6%
H
1.7
1.8
|
L
 16%
H
1.5
1.8
|
L
 -15.1%
H
1.4
2.2
|
L
 -12.1%
H
1.4
2.2
|
L
 40.3%
H
1.2
3.6
|
L
 -85.4%
H
1.1
12.9
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
23.9
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 10.2%
H
1.3
1.5
|
L
 3.7%
H
1.2
1.5
|
L
 56.7%
H
0.8
1.5
|
L
 243.9%
H
0.4
1.6
|
L
 48.4%
H
0.4
1.6
|
L
 -94.1%
H
0.4
24.4
|
L
 -98.0%
H
0.4
115
|
| Grace Therapeutics Inc |
|
34.3
|
2.1
|
L
 -0.9%
H
2.1
2.2
|
L
 1.4%
H
2.1
2.3
|
L
 -13.5%
H
1.9
2.5
|
L
 -9.8%
H
1.9
2.7
|
L
 -34.5%
H
1.8
5.2
|
L
 -13.2%
H
1.7
5.2
|
L
 -90.7%
H
1.7
23.4
|
L
 -97.0%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.6
|
1.5
|
L
 -0.7%
H
1.5
1.5
|
L
 6.3%
H
1.4
1.6
|
L
 4.8%
H
1.3
1.9
|
L
 -26.8%
H
1.3
2.2
|
L
 -65.8%
H
1.3
8.3
|
L
 -95.7%
H
1.3
176.4
|
L
 -98.4%
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
9.2
|
4.2
|
L
 5.8%
H
3.9
4.4
|
L
 26.1%
H
3.3
5.0
|
L
 50.4%
H
2.5
5.0
|
L
 194.4%
H
1.3
5.2
|
L
 -55.7%
H
1.3
10.8
|
L
 -96.5%
H
1.3
154
|
L
 -99.8%
H
1.3
3175
|
L
H
1.3
5900
|
| Agios Pharma Inc |
|
1,945.7
|
32.6
|
L
 1.0%
H
31.7
33.1
|
L
 8.6%
H
29.3
33.1
|
L
 -23.8%
H
29.2
42.9
|
L
 17.3%
H
26.4
44.1
|
L
 -8.9%
H
22.2
46
|
L
 25.1%
H
19.8
62.6
|
L
 -27.8%
H
16.8
62.6
|
L
 -20.4%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
426.4
|
105.3
|
L
 0.4%
H
103.3
107
|
L
 7.1%
H
92.7
108.1
|
L
 6.7%
H
92.4
108.1
|
L
 40.4%
H
64.7
108.1
|
L
 594.8%
H
14.5
108.1
|
L
 748.8%
H
8.4
108.1
|
L
 -35.1%
H
2.7
212.5
|
L
 -11.1%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
232.8
|
0.8
|
L
 -7.7%
H
0.8
0.9
|
L
 -36.4%
H
0.8
1.4
|
L
 -41.3%
H
0.8
1.4
|
L
 -27.6%
H
0.8
1.5
|
L
 -75.4%
H
0.8
3.4
|
L
 -44.4%
H
0.8
4.1
|
L
 -69.2%
H
0.2
4.1
|
L
 -89.5%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
47.8
|
7.7
|
L
 36.9%
H
5.7
7.7
|
L
 80.9%
H
4.2
7.7
|
L
 13%
H
4.0
7.7
|
L
 18.8%
H
4.0
7.7
|
L
 -0.5%
H
4.0
13.7
|
L
 -68.6%
H
3.8
46.3
|
L
 -98.1%
H
3.8
449.3
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
8,287.5
|
49.4
|
L
 0.5%
H
48.4
49.8
|
L
 0.8%
H
48.2
50.9
|
L
 -8.1%
H
47.7
53.9
|
L
 41.2%
H
35.2
55.7
|
L
 85.0%
H
25.2
55.7
|
L
 76.1%
H
22.0
55.7
|
L
 72.8%
H
21.2
55.7
|
L
 4.3%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
22.4
|
1.4
|
L
 1.4%
H
1.4
1.4
|
L
 16.5%
H
1.2
1.4
|
L
 17.5%
H
1.1
1.4
|
L
 -9.0%
H
1.0
1.8
|
L
 45.4%
H
0.8
2.1
|
L
 -96.6%
H
0.1
116
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
29,033.9
|
217.0
|
L
 -1.0%
H
215.6
223.5
|
L
 5.6%
H
208.0
234
|
L
 -30.6%
H
197.8
322.5
|
L
 -26.5%
H
197.8
380
|
L
 -50.6%
H
197.8
495.6
|
L
 16.4%
H
142.0
495.6
|
L
 8.4%
H
117.6
495.6
|
L
 184.0%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
67.6
|
0.8
|
L
 -3.7%
H
0.8
0.8
|
L
 6.8%
H
0.7
0.8
|
L
 -21%
H
0.7
1
|
L
 -35.3%
H
0.7
1.2
|
L
 -28.8%
H
0.7
2.2
|
L
 -52.1%
H
0.7
7.4
|
L
 -96.2%
H
0.7
25.4
|
L
H
0.7
309.6
|
| Alzamend Neuro Inc |
|
7.0
|
1.5
|
L
 6.6%
H
1.4
1.5
|
L
 11.5%
H
1.3
1.5
|
L
 25.9%
H
1.1
1.5
|
L
 36.5%
H
1
1.5
|
L
 -37.9%
H
0.8
2.7
|
L
 -99.7%
H
0.8
540
|
L
 -100.0%
H
0.8
5845.5
|
L
H
0.8
45292.5
|
| Amylyx Pharma Inc |
|
2,526.0
|
22.7
|
L
 -0.7%
H
22
23.0
|
L
 11.6%
H
19.3
24.6
|
L
 23.3%
H
16.5
24.6
|
L
 53.9%
H
12.4
24.6
|
L
 196.7%
H
7.6
24.6
|
L
 5.5%
H
1.6
24.6
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
895.5
|
20.3
|
L
 -2.3%
H
19.6
20.9
|
L
 1.9%
H
19.6
22.6
|
L
 6.8%
H
18.4
22.6
|
L
 6.9%
H
16.6
22.6
|
L
 -14.7%
H
16.6
31.3
|
L
 -67.4%
H
16.6
65.9
|
L
 1.1%
H
16.6
67.7
|
L
 13.1%
H
12.1
67.7
|
| Annexon Inc |
|
883.1
|
5.4
|
L
 -0.4%
H
5.3
5.5
|
L
 5.7%
H
4.9
5.7
|
L
 -9.3%
H
4.8
6.6
|
L
 -5.3%
H
4.5
6.6
|
L
 128.4%
H
2.0
7.2
|
L
 60.9%
H
1.3
8.4
|
L
 -74.7%
H
1.3
23.6
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
212.9
|
5.9
|
L
 -0.3%
H
5.7
6.1
|
L
 10.5%
H
5.4
6.3
|
L
 27.7%
H
4.3
6.3
|
L
 32.5%
H
3.7
6.3
|
L
 447.2%
H
1
6.9
|
L
 -27.9%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Niki BioSolutions Inc |
|
7.0
|
8.6
|
L
 -4.1%
H
8.5
8.8
|
L
 -12.7%
H
8.3
10.4
|
L
 9.8%
H
6
12.2
|
L
 2.6%
H
6
13.9
|
L
 -31.6%
H
6
44.7
|
L
 -56.5%
H
4.6
174.9
|
L
 -96.7%
H
4.6
294
|
L
H
4.6
3328
|
| Aprea Therapeutics Inc |
|
7.9
|
0.6
|
L
 -1.5%
H
0.6
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 -12.3%
H
0.6
0.8
|
L
 -34.7%
H
0.6
1
|
L
 -62.4%
H
0.6
1.8
|
L
 -83.5%
H
0.6
8.9
|
L
 -99.2%
H
0.6
113.4
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
538.3
|
4.3
|
L
 8.9%
H
4.3
4.6
|
L
 16.0%
H
3.7
4.6
|
L
 1.2%
H
3.6
4.6
|
L
 -0.7%
H
3.6
5.2
|
L
 10%
H
2.9
7.6
|
L
 113.4%
H
1.3
7.6
|
L
 12.0%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
200.4
|
7.1
|
L
 -4.9%
H
6.9
7.6
|
L
 22.4%
H
5.8
7.6
|
L
 -1.5%
H
5.5
7.6
|
L
 -23.5%
H
5.5
9.6
|
L
 -40.8%
H
5.5
24.2
|
L
 -75.2%
H
5.5
45
|
L
 -85.4%
H
5.5
65
|
L
 -80.0%
H
4.1
129.7
|
| Ardelyx Inc |
|
996.8
|
4
|
L
H
3.9
4.1
|
L
 -19.2%
H
3.9
5.1
|
L
 -25.7%
H
3.9
5.4
|
L
 -41%
H
3.9
6.8
|
L
 -23.2%
H
3.9
8.4
|
L
 1.0%
H
3.2
10.1
|
L
 151.6%
H
0.5
10.1
|
L
 -60.8%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,257.9
|
25.9
|
L
 2.5%
H
24.8
26.0
|
L
 -3.5%
H
24.8
29.2
|
L
 -9.9%
H
24.8
29.2
|
L
 22.4%
H
19.3
29.8
|
L
 75.5%
H
14.0
31.8
|
L
 176.0%
H
1.8
31.8
|
L
 17.9%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
2.4
|
0.7
|
L
 -2.8%
H
0.7
0.8
|
L
 -9.1%
H
0.7
0.8
|
L
 -31.4%
H
0.7
1.2
|
L
 -72.4%
H
0.7
2.6
|
L
 -97.2%
H
0.7
31.7
|
L
 -98.0%
H
0.7
85.8
|
L
 -99.7%
H
0.7
356.4
|
L
H
0.7
46656
|
| Assembly Biosciences Inc |
|
529.9
|
26.7
|
L
 0.2%
H
26.3
27.1
|
L
 6.5%
H
24.7
27.1
|
L
 -4.1%
H
24.5
28.2
|
L
 -10.1%
H
21.8
32.5
|
L
 11.6%
H
20.2
39.7
|
L
 110.2%
H
7.7
39.7
|
L
 -37.4%
H
7.7
47.3
|
L
 -61.6%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
540.1
|
4.3
|
L
 -3.2%
H
4.2
4.4
|
L
 7.3%
H
3.9
4.5
|
L
 -16.5%
H
3.5
5.4
|
L
 -20.3%
H
3.5
8.5
|
L
 -54.0%
H
3.5
14.5
|
L
 195.9%
H
0.9
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| ATAI Life Sciences N.V. |
|
2,682.2
|
7.3
|
L
H
7.2
7.3
|
L
 1.0%
H
7.2
7.3
|
L
 36.0%
H
4.8
7.3
|
L
 79.9%
H
3.7
7.3
|
L
 75.5%
H
3.3
7.3
|
L
 311.9%
H
1.0
7.3
|
L
 -49.3%
H
1.0
17.9
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
83.2
|
6.3
|
L
 4.7%
H
6.0
6.4
|
L
 22.1%
H
5.0
6.5
|
L
 6.8%
H
5.0
7
|
L
 36.7%
H
3.6
7.2
|
L
 -79%
H
1.8
174.6
|
L
 -96.1%
H
1.8
177.5
|
L
 -100.0%
H
1.8
33212
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
23.6
|
2.4
|
L
 0.4%
H
2.3
2.5
|
L
 14.5%
H
2.1
2.5
|
L
 0.4%
H
2.1
2.6
|
L
 -57.7%
H
1.7
5.7
|
L
 -79.9%
H
1.7
19.4
|
L
 -84.7%
H
1.7
34.7
|
L
 -95.3%
H
1.7
64.7
|
L
 -99.7%
H
1.7
756
|
| Atara Biotherapeutics Inc |
|
77.6
|
8.6
|
L
 1.9%
H
8.1
8.8
|
L
 2.7%
H
8.1
9.1
|
L
 -13.4%
H
7.4
10.1
|
L
 3.2%
H
7.4
12
|
L
 -21.4%
H
3.9
19.1
|
L
 -81.7%
H
0.4
58
|
L
 -97.2%
H
0.4
501
|
L
 -98.5%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
401.7
|
5.0
|
L
 -4.4%
H
5.0
5.3
|
L
 6.8%
H
4.6
5.3
|
L
 2.2%
H
3.8
5.3
|
L
 -7.6%
H
3.8
5.6
|
L
 48.5%
H
2.8
6.5
|
L
 41.8%
H
2.5
6.5
|
L
 -84.4%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
1,060.3
|
19.8
|
L
 7.9%
H
18
20
|
L
 8.3%
H
17.6
20
|
L
 -0.9%
H
17.5
20.5
|
L
 -8.3%
H
12.5
22.0
|
L
 121.4%
H
8.3
24.3
|
L
 13080%
H
0.0
34.5
|
L
 -45.4%
H
0.0
38.9
|
L
 -59.4%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
25.5
|
2.4
|
L
 0.9%
H
2.3
2.5
|
L
 6.7%
H
2.2
2.5
|
L
 8.2%
H
2.0
2.5
|
L
 -4.8%
H
2.0
2.6
|
L
 0.4%
H
1.7
3.1
|
L
 31.5%
H
1.0
3.5
|
L
 -97.0%
H
1.0
80.3
|
L
 -100.0%
H
1.0
320000
|
| Adagene Inc (ADR) |
|
268.9
|
4.1
|
L
 -1.0%
H
4.0
4.2
|
L
 8.5%
H
3.6
4.3
|
L
 5.7%
H
3.2
4.3
|
L
 10.3%
H
3.1
4.9
|
L
 87.6%
H
1.3
4.9
|
L
 206.0%
H
1.1
4.9
|
L
 -78.3%
H
0.9
19.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.5
|
6.0
|
L
 2.6%
H
6.0
6.0
|
L
 14.4%
H
5.7
6.2
|
L
 1.0%
H
5.0
6.5
|
L
 -13.0%
H
5.0
7.3
|
L
 -27.0%
H
5.0
12.1
|
L
 -46.8%
H
5
27.9
|
L
 -97.1%
H
5
205.6
|
L
H
5
750.4
|
| Amarin Corp (ADR) |
|
298.0
|
14.1
|
L
 -1.7%
H
14.0
14.4
|
L
 -1.1%
H
13.8
14.6
|
L
 -6.7%
H
13.5
15.2
|
L
 -6.3%
H
13.5
17.3
|
L
 -5.9%
H
13.0
20.9
|
L
 1116.4%
H
0.4
20.9
|
L
 190.9%
H
0.4
20.9
|
L
 323.7%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
15,693.3
|
255.6
|
L
 0.1%
H
251
257.4
|
L
 4.8%
H
239.6
257.6
|
L
 -7.2%
H
239.6
276.9
|
L
 7.1%
H
203.8
282.2
|
L
 33.5%
H
186.1
282.2
|
L
 169.2%
H
85.3
282.2
|
L
 104.2%
H
61.6
282.2
|
L
 1662.9%
H
14.1
282.2
|
| Alterity Therapeutics Ltd (ADR) |
|
82.3
|
4.5
|
L
 2.0%
H
4.4
4.7
|
L
 2.7%
H
4.3
4.7
|
L
 -15.6%
H
4.2
5.5
|
L
 -2.6%
H
3.8
5.9
|
L
 -15.9%
H
2.7
5.9
|
L
 62.7%
H
1
7
|
L
 -67.6%
H
1
14.2
|
L
 -92.4%
H
1
59.6
|
| Autolus Therapeutics PLC (ADR) |
|
550.9
|
2.1
|
L
 -1.9%
H
2.1
2.2
|
L
 38.9%
H
1.6
2.2
|
L
 22.5%
H
1.4
2.2
|
L
 31.9%
H
1.4
2.2
|
L
 -11.2%
H
1.2
2.5
|
L
 -30.8%
H
1.1
7.5
|
L
 -66.7%
H
1.1
7.9
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
502,012.8
|
161.9
|
L
 0.3%
H
160.3
162.7
|
L
 -4.6%
H
153.4
164.5
|
L
 -9.3%
H
153.4
175.9
|
L
 -11.5%
H
153.4
196.4
|
L
 -14.1%
H
153.4
212.7
|
L
 -14.1%
H
153.4
212.7
|
L
 -14.1%
H
153.4
212.7
|
L
 -14.1%
H
153.4
212.7
|
| Biofrontera Inc |
|
15.5
|
1.2
|
L
 -4.7%
H
1.2
1.3
|
L
 3.4%
H
1.2
1.3
|
L
 6.1%
H
1
1.3
|
L
 5.2%
H
0.7
1.3
|
L
 27.4%
H
0.6
1.3
|
L
 -88.8%
H
0.5
11.6
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
30,604.3
|
207.1
|
L
 -0.4%
H
206.3
210.0
|
L
 2.1%
H
199.6
212.2
|
L
 4.1%
H
186.0
218.6
|
L
 7.1%
H
184.9
219.7
|
L
 58.5%
H
127.7
219.7
|
L
 -23.6%
H
110.0
276.5
|
L
 -39.1%
H
110.0
351.9
|
L
 -28.5%
H
110.0
468.6
|
| Biomea Fusion Inc |
|
92.1
|
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 8.6%
H
1.1
1.3
|
L
 -3.1%
H
1.1
1.4
|
L
 -17.5%
H
1.1
1.7
|
L
 -17.5%
H
0.9
3.0
|
L
 -93.0%
H
0.9
22.7
|
L
 -90.0%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
7.7
|
4.0
|
L
 -1.5%
H
3.9
4.1
|
L
H
3.8
4.2
|
L
 0.3%
H
3.8
4.5
|
L
 -14.6%
H
3.8
5.7
|
L
 -28.4%
H
3.8
7.2
|
L
 -84.4%
H
3.8
31.2
|
L
 -98.3%
H
3.8
385.7
|
L
H
3.8
861.4
|
| Blue Water Biotech Inc |
|
16.0
|
0.9
|
L
 1.1%
H
0.9
0.9
|
L
 8.4%
H
0.8
1.0
|
L
 -8.2%
H
0.7
1.0
|
L
 136.8%
H
0.1
1.4
|
L
 -68.3%
H
0.1
6.7
|
L
 -6.3%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
32.5
|
0.8
|
L
 -9.2%
H
0.8
0.9
|
L
 -31.3%
H
0.8
1.3
|
L
 -47.0%
H
0.8
1.6
|
L
 -47.0%
H
0.8
1.9
|
L
 -60.5%
H
0.8
2.4
|
L
 -21%
H
0.7
4
|
L
 -97.1%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
287.7
|
4.1
|
L
 -1.4%
H
4.1
4.2
|
L
 6.5%
H
3.7
4.2
|
L
 -1.7%
H
3.7
4.4
|
L
 -14.6%
H
3.7
4.9
|
L
 -46.3%
H
3.7
9.2
|
L
 -81.7%
H
3.7
28.7
|
L
 -86.4%
H
3.7
62.1
|
L
H
3.7
62.1
|
| Biodexa Pharma PLC (ADR) |
|
1.6
|
1.6
|
L
 3.9%
H
1.5
1.7
|
L
 21.2%
H
1.3
1.7
|
L
 -38.2%
H
1.0
2.5
|
L
 -62.4%
H
1.0
4.1
|
L
 -95.5%
H
1.0
59.4
|
L
 -100.0%
H
1.0
301250
|
L
 -100.0%
H
1.0
97500000
|
L
 -100.0%
H
1.0
10000000000
|
| BeiGene Ltd (ADR) |
|
38,242.9
|
359
|
L
 3.1%
H
349.9
361.3
|
L
 13.6%
H
309.9
361.3
|
L
 18.6%
H
295.4
361.3
|
L
 15.0%
H
254.0
361.3
|
L
 24.6%
H
254.0
385.2
|
L
 79.0%
H
127.0
385.2
|
L
 12.5%
H
118.2
426.6
|
L
 1215.5%
H
26.4
426.6
|
| Bioline Rx Ltd (ADR) |
|
11.8
|
2.7
|
L
H
2.7
2.9
|
L
 -3.9%
H
2.6
3.0
|
L
 -10.6%
H
2.6
3.2
|
L
 -11.7%
H
2.5
4.0
|
L
 -23.9%
H
2.2
4.6
|
L
 -95.6%
H
0.1
101.2
|
L
 -97.8%
H
0.1
126
|
L
 -99.4%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,704.6
|
167.3
|
L
 2.6%
H
163.2
167.5
|
L
 5.5%
H
152.9
167.5
|
L
 9.2%
H
144.1
167.5
|
L
 8.0%
H
130
167.5
|
L
 139.4%
H
60
200
|
L
 625.3%
H
20.3
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
20.9
|
3.9
|
L
 1.1%
H
3.8
3.9
|
L
 -0.5%
H
3.8
4.1
|
L
 10.0%
H
3.3
4.2
|
L
 -27.3%
H
3.2
5.5
|
L
 -48.1%
H
3.2
21.4
|
L
 152.3%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
223.0
|
3.9
|
L
 -5.9%
H
3.8
4.1
|
L
H
3.7
4.7
|
L
 -82.9%
H
3.0
22.6
|
L
 -87.3%
H
3.0
32.6
|
L
 -57.6%
H
3.0
40.4
|
L
 -34.7%
H
2.7
40.4
|
L
 -16.8%
H
2.6
40.4
|
L
 -89.7%
H
0.9
42.5
|
| Crescent Biopharma Inc |
|
-
|
17.3
|
L
 2.9%
H
16.7
17.7
|
L
 19.8%
H
14
17.7
|
L
 3.4%
H
14.0
17.8
|
L
 -7.6%
H
14.0
22.5
|
L
 34.9%
H
8.7
27.4
|
L
 237.8%
H
4.8
27.4
|
L
 66.6%
H
0.9
27.4
|
L
 -66.4%
H
0.9
90.3
|
| Cullinan Oncology Inc |
|
1,176.4
|
18.3
|
L
 3.1%
H
17.3
18.3
|
L
 10.8%
H
16.0
18.4
|
L
 -0.5%
H
16
18.4
|
L
 25.6%
H
11.7
19.4
|
L
 150.4%
H
5.7
19.4
|
L
 76.4%
H
5.7
30.2
|
L
 -31.5%
H
5.7
30.3
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
191.6
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 -12.1%
H
1.1
1.5
|
L
 -23.9%
H
1.1
1.6
|
L
 -29.1%
H
1.1
2.1
|
L
 51.2%
H
0.8
2.6
|
L
 -73.0%
H
0.7
5.5
|
L
 -90.6%
H
0.7
19.3
|
L
 -95.8%
H
0.7
32.0
|
| Cingulate Inc |
|
70.7
|
5.3
|
L
 -1.7%
H
5.1
5.4
|
L
 9.6%
H
4.7
5.4
|
L
 6.1%
H
4.2
5.4
|
L
 -0.4%
H
3.2
6.0
|
L
 25.9%
H
3.2
11.9
|
L
 872.2%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
65.9
|
5.2
|
L
 -2.3%
H
4.1
5.4
|
L
 2.8%
H
4.1
5.6
|
L
 -17.4%
H
4.1
6.6
|
L
 -29.1%
H
4.1
7.7
|
L
 40.2%
H
3.5
13.5
|
L
 -63.0%
H
2.3
15.6
|
L
 -97.3%
H
2.3
196.8
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
20.8
|
2.6
|
L
 1.2%
H
2.6
2.6
|
L
 1.2%
H
2.5
2.7
|
L
 -6.1%
H
2.3
2.9
|
L
 -16.1%
H
2.2
3.3
|
L
 -45.0%
H
2.2
6.5
|
L
 -95.0%
H
2.2
133.5
|
L
 -99.1%
H
2.2
327
|
L
 -100.0%
H
2.2
10410
|
| Compass Therapeutics Inc |
|
399.8
|
2.2
|
L
 3.3%
H
2.1
2.2
|
L
 16.2%
H
1.9
2.2
|
L
 -3.9%
H
1.9
2.4
|
L
 21.3%
H
1.8
2.5
|
L
 -17.8%
H
1.6
6.9
|
L
 -15.6%
H
0.8
6.9
|
L
 -53.3%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
7.5
|
5.1
|
L
 -4.7%
H
5.0
5.1
|
L
 -11.9%
H
5.0
5.8
|
L
 -3.6%
H
4.6
6
|
L
 -29.6%
H
3.9
7.6
|
L
 -23.4%
H
1.9
10.6
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
77850000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
41.3
|
0.5
|
L
 -6.3%
H
0.4
0.5
|
L
 -25%
H
0.4
0.7
|
L
 -25%
H
0.4
0.7
|
L
 -81.1%
H
0.4
3.1
|
L
 -37.5%
H
0.4
3.6
|
L
 -52.1%
H
0.4
3.6
|
L
H
0.4
10.9
|
L
H
0.4
10.9
|
| Cocrystal Pharma Inc |
|
14.9
|
1.1
|
L
 1.9%
H
1.1
1.2
|
L
 31.7%
H
0.9
1.2
|
L
 6.9%
H
0.8
1.2
|
L
 -25%
H
0.8
1.4
|
L
 -33.3%
H
0.8
2.7
|
L
 -65.6%
H
0.8
3.3
|
L
 -91.6%
H
0.8
14.8
|
L
 -99.3%
H
0.8
194.4
|
| Collegium pharma Inc |
|
882.2
|
27.2
|
L
 -7.7%
H
27.1
29.3
|
L
 -23.1%
H
27.1
36.5
|
L
 -24.0%
H
27.1
37.7
|
L
 -28.0%
H
27.1
38.5
|
L
 -22.1%
H
27.1
50.8
|
L
 13.6%
H
21.0
50.8
|
L
 36.7%
H
14.0
50.8
|
L
 122.0%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
12,348.1
|
114.2
|
L
 3.1%
H
110.1
114.6
|
L
 -0.2%
H
107.3
115
|
L
 22.5%
H
84.9
122.2
|
L
 118.5%
H
50.6
122.2
|
L
 58.0%
H
28.7
122.2
|
L
 278.6%
H
20.8
122.2
|
L
 427.9%
H
15.8
122.2
|
L
 1788.1%
H
5.2
122.2
|
| Cosmos Health Inc |
|
13.7
|
0.2
|
L
 -4.4%
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -15.4%
H
0.2
0.4
|
L
 -33.3%
H
0.2
0.4
|
L
 -72.5%
H
0.2
1.3
|
L
 -81.0%
H
0.2
2.1
|
L
 -99.8%
H
0.2
150
|
L
 -99.9%
H
0.2
312.5
|
| Cumberland Pharma Inc |
|
116.7
|
7.8
|
L
 -0.1%
H
7.7
8.5
|
L
 50.4%
H
5.4
8.5
|
L
 29.0%
H
5.4
8.5
|
L
 66.5%
H
4.4
8.5
|
L
 141.2%
H
1.9
8.5
|
L
 372.1%
H
1.0
8.5
|
L
 176.2%
H
1.0
8.5
|
L
 70.8%
H
1.0
8.5
|
| Corbus Pharma Holdings Inc |
|
176.6
|
9.5
|
L
 -7.0%
H
9.4
10.3
|
L
 5.5%
H
8.7
10.3
|
L
 -2.1%
H
8.5
10.3
|
L
 -13.7%
H
7.1
12.9
|
L
 12.2%
H
7.1
20.6
|
L
 53.8%
H
3.0
61.9
|
L
 -77.3%
H
2.1
61.9
|
L
 -89.5%
H
2.1
323.4
|
| Crinetics Pharma Inc |
|
8,927.9
|
84.2
|
L
 0.1%
H
84.0
84.3
|
L
 0.8%
H
83.6
84.3
|
L
 0.6%
H
83.5
84.3
|
L
 124.5%
H
32.3
84.3
|
L
 213.4%
H
26.5
84.3
|
L
 404.5%
H
15.8
84.3
|
L
 398.5%
H
15.2
84.3
|
L
H
10.6
84.3
|
| Corvus Pharma Inc |
|
1,155.8
|
13.7
|
L
 -1.3%
H
13.4
14.2
|
L
 3.6%
H
12.8
14.4
|
L
 -15.2%
H
12.5
16.2
|
L
 -11.6%
H
10.8
16.9
|
L
 218.8%
H
4.3
27.0
|
L
 494.8%
H
1.1
27.0
|
L
 567.0%
H
0.6
27.0
|
L
 -1.9%
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
749.6
|
3.4
|
L
 -0.6%
H
3.4
3.5
|
L
 11.0%
H
3.0
3.6
|
L
 -13.1%
H
3.0
4.0
|
L
 -13.6%
H
2.8
4.1
|
L
 46.4%
H
1.7
8.2
|
L
 111.0%
H
0.4
8.2
|
L
 -33.7%
H
0.4
8.2
|
L
 -68.9%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
5.0
|
0.9
|
L
 -5.3%
H
0.9
1.0
|
L
 1.1%
H
0.9
1.0
|
L
 -2.2%
H
0.8
1.0
|
L
 2.3%
H
0.6
2.8
|
L
 -89.8%
H
0.6
9.5
|
L
 -100.0%
H
0.6
2721.6
|
L
 -100.0%
H
0.6
21960
|
L
 -100.0%
H
0.6
784800
|
| Cyclerion Therapeutics Inc |
|
16.8
|
3.6
|
L
 0.3%
H
3.5
3.7
|
L
 4.1%
H
3.4
3.7
|
L
 -8.9%
H
3.4
3.9
|
L
 15.5%
H
2.9
4.0
|
L
 56.3%
H
1.0
8.5
|
L
 3.5%
H
1.0
8.5
|
L
 -94.5%
H
1.0
72.5
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
10,520.9
|
77.5
|
L
 1.0%
H
75.7
77.9
|
L
 0.5%
H
74.9
81.8
|
L
 -10.0%
H
74.9
86.5
|
L
 0.8%
H
66.6
88.3
|
L
 127.2%
H
32.9
88.3
|
L
 143.7%
H
26.0
110
|
L
 143.0%
H
26.0
110
|
L
 532.1%
H
5.8
110
|
| Cellectis (ADR) |
|
277.9
|
2.8
|
L
 -2.8%
H
2.6
2.9
|
L
 0.4%
H
2.4
3.0
|
L
 -12.9%
H
2.4
3.1
|
L
 -28.3%
H
2.4
4.2
|
L
 6.2%
H
2.4
5.5
|
L
 50.8%
H
1.0
5.5
|
L
 -81.3%
H
1.0
15.5
|
L
 -90.1%
H
1.0
38.9
|
| Connect Biopharma Holdings Ltd (ADR) |
|
119.8
|
2.2
|
L
 -2.3%
H
2.1
2.2
|
L
 6.4%
H
2.0
2.3
|
L
 -19.2%
H
2.0
2.8
|
L
 -8.9%
H
1.9
2.8
|
L
 3.9%
H
1.2
3.8
|
L
 131.2%
H
0.5
3.8
|
L
 -91.8%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
20.4
|
1.4
|
L
 -2.9%
H
1.4
1.4
|
L
 11.5%
H
1.2
1.4
|
L
 -34.3%
H
1.1
2.1
|
L
 -50.6%
H
1.1
3.1
|
L
 -29.2%
H
1.1
3.8
|
L
 -84.5%
H
0.3
9.5
|
L
 -93.3%
H
0.3
30.1
|
L
 -99.6%
H
0.3
429.6
|
| Journey Medical Corp |
|
177.3
|
6.4
|
L
 0.2%
H
6.3
6.6
|
L
 1.1%
H
6.3
6.8
|
L
 -8%
H
6
7.5
|
L
 27.0%
H
4.8
7.5
|
L
 -14.9%
H
4.3
9.6
|
L
 163.9%
H
1.8
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Dermata Therapeutics Inc |
|
4.5
|
1.1
|
L
 1.8%
H
1.1
1.1
|
L
 -4.3%
H
1.0
1.2
|
L
 -16.4%
H
1.0
1.4
|
L
 -11.1%
H
1.0
1.5
|
L
 -82.7%
H
1.0
6.6
|
L
 -4.3%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
896.8
|
14.3
|
L
 5.9%
H
13.4
14.5
|
L
 5.7%
H
13.0
14.7
|
L
 -11.3%
H
13
16.7
|
L
 -27.7%
H
13
20.9
|
L
 45.3%
H
8.7
26.2
|
L
 -6.7%
H
0.5
26.2
|
L
 -70.4%
H
0.5
59.9
|
L
 -95.8%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
50.5
|
5.2
|
L
 -0.6%
H
5.2
5.7
|
L
 2.5%
H
4.8
5.8
|
L
 -25.4%
H
4.5
7.2
|
L
 -67.9%
H
4.5
17.1
|
L
 147.2%
H
0.7
20.3
|
L
 -18.6%
H
0.7
20.3
|
L
 -83.9%
H
0.7
84
|
L
 -99.4%
H
0.7
882
|
| Eledon Pharma Inc |
|
284.1
|
3.7
|
L
 -0.3%
H
3.6
3.9
|
L
 8.9%
H
3.3
3.9
|
L
 -10.9%
H
3.3
4.2
|
L
 -5.2%
H
3.3
4.5
|
L
 35.3%
H
1.4
4.6
|
L
 204.1%
H
1.1
5.4
|
L
 -43.4%
H
1.1
8.5
|
L
 -98.0%
H
1.1
338.6
|
| Enanta Pharma Inc |
|
401.6
|
13.8
|
L
 0.3%
H
13.6
13.9
|
L
 9.6%
H
12.3
13.9
|
L
 -3.1%
H
12.3
14.5
|
L
 -10.0%
H
10.9
15.9
|
L
 100.1%
H
6.5
17.2
|
L
 -17.3%
H
4.1
17.8
|
L
 -69.4%
H
4.1
102
|
L
 -38.6%
H
4.1
127.8
|
| Entera Bio Ltd |
|
149.8
|
3.0
|
L
 5.9%
H
2.7
3.1
|
L
 1.7%
H
2.7
3.1
|
L
 78.8%
H
1.6
4.2
|
L
 133.9%
H
1.2
4.2
|
L
 67.0%
H
0.9
4.2
|
L
 310.8%
H
0.5
4.2
|
L
 -45.1%
H
0.5
5.8
|
L
H
0.5
10.2
|
| Evolus Inc |
|
500.0
|
7.6
|
L
 -0.3%
H
7.2
7.6
|
L
 29.6%
H
5.8
7.8
|
L
 10.5%
H
5.4
7.8
|
L
 19.0%
H
5.4
7.8
|
L
 28.3%
H
3.9
8.0
|
L
 -18.3%
H
3.9
17.8
|
L
 -34.3%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
6,289.9
|
18.1
|
L
 -1.6%
H
17.8
18.6
|
L
 -0.2%
H
17.1
19
|
L
 -5.5%
H
17.1
21.6
|
L
 79.1%
H
9.8
21.6
|
L
 1194.3%
H
1.3
24.3
|
L
 589.0%
H
1.0
24.3
|
L
 -14.3%
H
1.0
24.5
|
L
H
1.0
24.5
|
| Eterna Therapeutics Inc |
|
5.3
|
4.5
|
L
 7.6%
H
4.2
4.8
|
L
 38.1%
H
3.3
4.8
|
L
 -23.6%
H
3.3
9.9
|
L
 -39.8%
H
3.3
15.9
|
L
 -89.3%
H
3.2
71.5
|
L
 -99.6%
H
3.2
1042.5
|
L
 -100.0%
H
3.2
102225
|
L
 -100.0%
H
3.2
605025
|
| Eton Pharma Inc |
|
1,196.2
|
43.7
|
L
 -2.1%
H
43.1
45.4
|
L
 -5.9%
H
43.1
48.4
|
L
 17.0%
H
35
50.2
|
L
 47.3%
H
26.7
50.2
|
L
 154.8%
H
14.3
50.2
|
L
 1554.2%
H
2.5
50.2
|
L
 806.0%
H
2.0
50.2
|
L
H
2.0
50.2
|
| Exelixis Inc |
|
13,122.5
|
53.0
|
L
 -2.1%
H
52.5
54.0
|
L
 -0.1%
H
51.8
56.9
|
L
 -7.3%
H
51.8
57.3
|
L
 10.0%
H
48.1
57.6
|
L
 40.4%
H
33.8
57.6
|
L
 156.8%
H
18.6
57.6
|
L
 201.8%
H
14.9
57.6
|
L
 387.2%
H
10.0
57.6
|
| Hyperion DeFi Inc |
|
39.6
|
2.6
|
L
 -3.3%
H
2.6
2.7
|
L
 -1.1%
H
2.5
2.8
|
L
 -16.4%
H
2.3
3.2
|
L
 -27.5%
H
2.3
4.1
|
L
 -65.0%
H
2.3
15
|
L
 -98.4%
H
0.0
205.6
|
L
 -99.2%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,126.8
|
13.1
|
L
 -5.9%
H
13.0
14.3
|
L
 6.7%
H
11.5
14.3
|
L
 -11.9%
H
11.5
14.8
|
L
 -4.3%
H
11.3
15.9
|
L
 27.8%
H
9.7
19.1
|
L
 -0.5%
H
3.9
31.0
|
L
 41.0%
H
2.2
31.0
|
L
 -67.3%
H
2.2
41.5
|
| Fortress Biotech Inc |
|
91.4
|
2.8
|
L
 3%
H
2.6
2.8
|
L
 -12.1%
H
2.6
3.0
|
L
 -16.4%
H
2.6
3.8
|
L
 15.1%
H
2.2
3.8
|
L
 51.1%
H
1.8
4.5
|
L
 -66.0%
H
1.2
8.4
|
L
 -94.4%
H
1.2
57.2
|
L
 -93.8%
H
1.2
91.5
|
| Kyntra Bio Inc |
|
28.2
|
7.0
|
L
 -4.1%
H
7.0
7.3
|
L
 3.6%
H
6.8
7.3
|
L
 -4.8%
H
6.7
7.7
|
L
 0.3%
H
6.6
8.0
|
L
 -20.0%
H
6.3
12.6
|
L
 -79.6%
H
4.5
73.3
|
L
 -98.0%
H
4.5
642.3
|
L
 -98.5%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
466.4
|
15.7
|
L
 0.5%
H
15.3
16.7
|
L
 -0.1%
H
14.7
17.0
|
L
 24.5%
H
10.8
23.6
|
L
 191.8%
H
5.0
23.6
|
L
 861.4%
H
1.6
23.6
|
L
 -30.4%
H
1.3
53.8
|
L
 -87.3%
H
1.3
160.2
|
L
H
1.3
572.4
|
| Frequency Therapeutics Inc |
|
-
|
13.5
|
L
 1.8%
H
13
13.7
|
L
 30.1%
H
10.2
13.7
|
L
 -5.7%
H
9.8
14.7
|
L
 12.0%
H
9.1
15.6
|
L
 -15.7%
H
5.2
55.9
|
L
 -62%
H
5.2
55.9
|
L
 -96.8%
H
5.2
421
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
286.1
|
3.8
|
L
 -3.6%
H
3.7
3.9
|
L
 4.8%
H
3.5
3.9
|
L
 4.5%
H
3.4
3.9
|
L
 -46.5%
H
2.8
7.5
|
L
 -42.2%
H
2.8
15.7
|
L
 -5.5%
H
2.3
15.7
|
L
 -55.0%
H
2.3
33.1
|
L
H
2.3
33.1
|
| GH Research PLC |
|
2,026.0
|
29.5
|
L
 -2.4%
H
29.5
30.4
|
L
 5.2%
H
27.4
31.4
|
L
 8.6%
H
25
31.4
|
L
 37.9%
H
19.5
31.4
|
L
 138.0%
H
11.3
31.4
|
L
 139.5%
H
5.1
31.4
|
L
 60.1%
H
5.1
31.4
|
L
H
5.1
31.4
|
| Galmed Pharma Ltd |
|
4.9
|
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 -4.8%
H
0.6
0.6
|
L
 3.5%
H
0.5
0.6
|
L
 -3.3%
H
0.4
0.8
|
L
 -59.3%
H
0.4
1.7
|
L
 -94.6%
H
0.2
13.6
|
L
 -99.9%
H
0.2
610.2
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
1,818.3
|
29.5
|
L
 -1.3%
H
29.2
30.3
|
L
 1.9%
H
28.4
31.8
|
L
 -4.0%
H
26.3
34.9
|
L
 22.3%
H
18.6
34.9
|
L
 774.0%
H
2.5
38.3
|
L
 1072.2%
H
0.5
38.3
|
L
 565.3%
H
0.5
38.3
|
L
H
0.5
38.3
|
| GlycoMimetics Inc |
|
1,118.3
|
17.3
|
L
 2.9%
H
16.7
17.7
|
L
 19.8%
H
14
17.7
|
L
 3.4%
H
14.0
17.8
|
L
 -7.6%
H
14.0
22.5
|
L
 34.9%
H
8.7
27.4
|
L
 -89.1%
H
8.7
353
|
L
 -91.6%
H
8.7
416
|
L
 -97.8%
H
8.7
2605
|
| Genelux Corp |
|
122.0
|
2.7
|
L
 2.3%
H
2.6
2.7
|
L
 -7.5%
H
2.5
3.1
|
L
 -8.7%
H
2.5
3.1
|
L
 -12.5%
H
2.5
3.3
|
L
 -13.7%
H
2.3
8.5
|
L
 -90.9%
H
1.6
30.4
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
2.1
|
4.2
|
L
 -1.9%
H
4.0
4.6
|
L
 -30.1%
H
4
5.5
|
L
 648.2%
H
0.5
10.0
|
L
 381.6%
H
0.4
10.0
|
L
 1895.2%
H
0.1
13.0
|
L
 554.7%
H
0.1
13.0
|
L
 42.0%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
88.0
|
0.2
|
L
H
0.2
0.2
|
L
 5.9%
H
0.2
0.2
|
L
H
0.1
0.3
|
L
 -45.5%
H
0.1
0.4
|
L
 -89.8%
H
0.1
3.9
|
L
 -85%
H
0.1
3.9
|
L
 -97.8%
H
0.1
15.2
|
L
H
0.1
27.2
|
| GT Biopharma Inc |
|
11.5
|
0.3
|
L
H
0.3
0.3
|
L
 10.3%
H
0.3
0.3
|
L
 -28.9%
H
0.3
0.5
|
L
 -15.8%
H
0.3
0.6
|
L
 -82.1%
H
0.3
1.8
|
L
 14.3%
H
0.2
10.7
|
L
 -97.1%
H
0.2
11.2
|
L
 -100.0%
H
0.2
1519.8
|
| Genenta Science SpA (ADR) |
|
62.7
|
1.3
|
L
H
1.3
1.3
|
L
 -12.8%
H
1.2
1.6
|
L
 -18.2%
H
1.2
1.7
|
L
 106.4%
H
0.6
2.6
|
L
 -65.0%
H
0.6
10
|
L
 -77.6%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Structure Therapeutics Inc (ADR) |
|
3,823.8
|
53.8
|
L
 1.2%
H
51.9
53.9
|
L
 12.0%
H
46.6
54.8
|
L
 -2.4%
H
44.8
55.0
|
L
 37.6%
H
35.8
57.1
|
L
 229.9%
H
16
94.9
|
L
 91.4%
H
13.2
94.9
|
L
H
13.2
94.9
|
L
H
13.2
94.9
|
| Grifols SA (ADR) - Level III |
|
5,478.7
|
8.1
|
L
 1.4%
H
7.9
8.1
|
L
 2.3%
H
7.8
8.1
|
L
 10.4%
H
7
8.4
|
L
 -0.6%
H
7.0
8.4
|
L
 -24.5%
H
7.0
10.8
|
L
 -20.1%
H
5.3
12.2
|
L
 -45.9%
H
5.3
15.9
|
L
 -51.5%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
19.7
|
0.8
|
L
 4.0%
H
0.8
0.8
|
L
 -1.3%
H
0.7
0.8
|
L
 -13.2%
H
0.7
0.9
|
L
 17.9%
H
0.5
2.5
|
L
 -33.6%
H
0.5
2.5
|
L
 -68.4%
H
0.5
3.8
|
L
 -97.6%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
18.5
|
0.4
|
L
 -5%
H
0.4
0.4
|
L
 8.6%
H
0.4
0.4
|
L
H
0.3
0.5
|
L
 -44.1%
H
0.3
0.7
|
L
 -67.5%
H
0.3
2.4
|
L
 -85.0%
H
0.3
8.2
|
L
 -97.4%
H
0.3
19.7
|
L
H
0.3
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,271.2
|
39
|
L
 1.5%
H
38.3
39.3
|
L
 10.7%
H
34.5
40.0
|
L
 2.1%
H
32.3
40.0
|
L
 25.9%
H
29.3
40.0
|
L
 14.1%
H
25.5
40.9
|
L
 17.7%
H
18.6
41.6
|
L
 45.7%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,517.1
|
40.7
|
L
 0.6%
H
39.6
41.1
|
L
 5.0%
H
38
41.1
|
L
 -5.2%
H
36.3
47.5
|
L
 6.5%
H
28.5
47.5
|
L
 18.2%
H
28.5
54.9
|
L
 105.6%
H
7.6
59.2
|
L
 346.8%
H
5.4
59.2
|
L
 915.0%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
2,181.4
|
12.6
|
L
 0.3%
H
12.4
12.7
|
L
 12.8%
H
11.3
12.7
|
L
 14.3%
H
10.6
12.7
|
L
 -4.4%
H
9.8
13.1
|
L
 -16.3%
H
9.8
18.3
|
L
 -14.9%
H
9.8
21.9
|
L
 -70.8%
H
7.4
43.2
|
L
 -3.6%
H
7.4
43.9
|
| ImmunityBio Inc |
|
7,938.2
|
7.5
|
L
 -2.0%
H
7.4
7.7
|
L
 4.5%
H
6.7
7.7
|
L
 -15.6%
H
6.7
8.9
|
L
 -12.0%
H
6.7
9.6
|
L
 207.0%
H
2.0
12.4
|
L
 348.5%
H
1.3
12.4
|
L
 -32.8%
H
1.2
12.4
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
3,537.1
|
36.7
|
L
 -0.8%
H
36.2
37.5
|
L
 3.5%
H
34.6
37.5
|
L
 -1.5%
H
34.0
37.9
|
L
 29.7%
H
26.8
40.6
|
L
 59.1%
H
22.4
40.6
|
L
 48.1%
H
13.5
47.7
|
L
 58.4%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
386.3
|
2.5
|
L
 -0.4%
H
2.4
2.5
|
L
 12.8%
H
2.2
2.5
|
L
 20.6%
H
1.9
2.5
|
L
 19.4%
H
1.5
2.5
|
L
 72.0%
H
1.3
2.5
|
L
 1.2%
H
0.8
4.2
|
L
 -80.9%
H
0.8
15.2
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
721.2
|
10.1
|
L
 4.2%
H
9.7
10.3
|
L
 21.8%
H
7.8
10.3
|
L
 -8.7%
H
7.8
11.2
|
L
 3.9%
H
7.7
12.1
|
L
 323.9%
H
1.9
12.1
|
L
 424.9%
H
1.3
12.1
|
L
H
0.7
12.1
|
L
H
0.7
12.1
|
| Immuneering Corp (Class A) |
|
293.1
|
4.5
|
L
 0.4%
H
4.5
4.7
|
L
 9.7%
H
4.1
4.7
|
L
 -15.5%
H
4.0
5.3
|
L
 -13.2%
H
3.9
6.9
|
L
 39.4%
H
2.9
10.1
|
L
 -54.7%
H
1
10.5
|
L
 -84.7%
H
1
33.3
|
L
H
1
34.0
|
| Immatics N.V |
|
1,328.5
|
9.7
|
L
 0.7%
H
9.6
9.9
|
L
 12.2%
H
8.4
9.9
|
L
 -2.4%
H
8.2
9.9
|
L
 -14.5%
H
8.2
11.9
|
L
 57.3%
H
5.1
12.4
|
L
 -18.9%
H
3.3
13.8
|
L
 -19.4%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
192.1
|
14.1
|
L
 -1.4%
H
13.9
14.5
|
L
 0.9%
H
13.7
15.6
|
L
 -4.6%
H
12.7
15.8
|
L
 21.2%
H
10.9
15.8
|
L
 61.7%
H
5.1
15.8
|
L
 -22.5%
H
5.1
21.1
|
L
 -85.6%
H
5.1
145
|
L
 -99.4%
H
5.1
3900
|
| Incyte |
|
24,637.9
|
121.6
|
L
 0.8%
H
120.5
122.7
|
L
 1.7%
H
115.8
124.6
|
L
 2.6%
H
110.6
132.6
|
L
 23.3%
H
92.2
132.6
|
L
 55.1%
H
78.2
132.6
|
L
 85.8%
H
50.3
132.6
|
L
 61.4%
H
50.3
132.6
|
L
 40.6%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
158.6
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -7.8%
H
1.1
1.5
|
L
 -52.4%
H
1.1
3
|
L
 -36.7%
H
0.9
6.0
|
L
 -83.4%
H
0.9
8.7
|
L
 -33.9%
H
0.3
13.4
|
L
 -87.9%
H
0.3
28.8
|
L
 -99.7%
H
0.3
8800
|
| Indivior PLC |
|
4,540.0
|
38.5
|
L
 -0.9%
H
38.0
39.1
|
L
 -3.9%
H
35.8
41.2
|
L
 -6.9%
H
35.8
41.8
|
L
 -2.6%
H
32.4
42.8
|
L
 74.9%
H
21.8
42.8
|
L
 61.0%
H
7.3
42.8
|
L
 1502.9%
H
2.2
42.8
|
L
 912.4%
H
0.4
42.8
|
| InMed Pharma Inc |
|
7.5
|
1.4
|
L
 -4.1%
H
1.4
1.5
|
L
 -4.1%
H
1.4
1.5
|
L
 -15.1%
H
1.4
2.3
|
L
 116.9%
H
0.6
2.3
|
L
 -37.1%
H
0.6
2.5
|
L
 -92.4%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1320
|
L
 -99.9%
H
0.6
32175
|
| Inovio Pharma Inc |
|
76.5
|
0.7
|
L
 10.5%
H
0.7
0.8
|
L
 8.8%
H
0.6
0.8
|
L
 -37.8%
H
0.6
1.2
|
L
 -49.3%
H
0.6
1.6
|
L
 -47.5%
H
0.6
3.0
|
L
 85%
H
0.3
14.8
|
L
 -92.3%
H
0.3
14.8
|
L
 -91.8%
H
0.3
33.8
|
| Insmed Inc |
|
29,426.9
|
134.8
|
L
 2.8%
H
129.5
135.5
|
L
 36.7%
H
96.4
137.7
|
L
 13.9%
H
96.4
137.7
|
L
 33.0%
H
90.4
137.7
|
L
 23%
H
90.4
212.8
|
L
 526.2%
H
21.2
212.8
|
L
 447.8%
H
16.0
212.8
|
L
 1042.9%
H
10.2
212.8
|
| Innoviva Inc |
|
1,494.0
|
20.7
|
L
 0.8%
H
20.4
20.8
|
L
 -1.4%
H
20.2
22.1
|
L
 -6.9%
H
20.2
22.7
|
L
 -9.7%
H
20.2
24.2
|
L
 12.8%
H
16.5
25.1
|
L
 51.4%
H
12.2
25.1
|
L
 36.4%
H
10.6
25.1
|
L
 65.8%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
9,462.5
|
56.9
|
L
 0.7%
H
56.1
57.7
|
L
 10.0%
H
52.2
57.7
|
L
 -11.4%
H
50
64.4
|
L
 -24.8%
H
50
86.7
|
L
 36.7%
H
40.4
86.7
|
L
 42.4%
H
24.0
86.7
|
L
 47.7%
H
24.0
86.7
|
L
 56.7%
H
24.0
86.7
|
| Ironwood Pharma Inc (Class A) |
|
669.2
|
4.1
|
L
 -6.3%
H
4.0
4.3
|
L
 -4.3%
H
3.9
4.6
|
L
 -13.3%
H
3.6
4.7
|
L
 -4.0%
H
3.1
4.9
|
L
 350%
H
0.8
5.8
|
L
 -57.9%
H
0.5
15.7
|
L
 -69.5%
H
0.5
15.7
|
L
 -63.2%
H
0.5
17.7
|
| I-Mab (ADR) |
|
204.0
|
1.8
|
L
 1.1%
H
1.7
1.8
|
L
 10.6%
H
1.6
1.8
|
L
 -4.8%
H
1.6
2.0
|
L
 -19.6%
H
1.5
2.3
|
L
 -48.1%
H
1.5
6.8
|
L
 -30.9%
H
0.6
6.8
|
L
 -97.7%
H
0.6
80.9
|
L
H
0.6
85.4
|
| Immuron Ltd (ADR) |
|
8.9
|
1.1
|
L
 6.8%
H
1.0
1.2
|
L
 0.9%
H
1.0
1.2
|
L
 -12.7%
H
1.0
1.3
|
L
 37.5%
H
0.8
1.6
|
L
 -35.7%
H
0.7
2.4
|
L
 -46.9%
H
0.7
6.0
|
L
 -77.3%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
208.5
|
2.2
|
L
 28.3%
H
2.1
2.5
|
L
 26.9%
H
1.6
2.5
|
L
 24.0%
H
1.6
2.5
|
L
 57.5%
H
1.3
2.6
|
L
 5.7%
H
1.2
2.6
|
L
 -22.9%
H
1.2
3.5
|
L
 -34.1%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Jaguar Health Inc |
|
4.1
|
0.8
|
L
 -12.6%
H
0.8
1
|
L
 -17%
H
0.8
1.1
|
L
 -65.0%
H
0.8
2.4
|
L
 -72.3%
H
0.8
4.1
|
L
 -98.9%
H
0.8
92.8
|
L
 -100.0%
H
0.8
31395
|
L
 -100.0%
H
0.8
16065000
|
L
 -100.0%
H
0.8
880621875
|
| Jazz Pharma PLC |
|
16,651.9
|
256.5
|
L
 0.0%
H
255.5
261.3
|
L
 1.5%
H
247.4
265.0
|
L
 3.9%
H
233.5
265.0
|
L
 13.6%
H
220.7
265.0
|
L
 130.5%
H
110.3
265.0
|
L
 92.9%
H
95.5
265.0
|
L
 69.9%
H
95.5
265.0
|
L
 71.0%
H
86.9
265.0
|
| Kala Pharma Inc |
|
14.7
|
0.8
|
L
 1.3%
H
0.7
0.8
|
L
H
0.7
0.9
|
L
 -43.7%
H
0.6
1.4
|
L
 -80.8%
H
0.6
4.0
|
L
 -99.8%
H
0.6
1030
|
L
 -99.9%
H
0.6
1030
|
L
 -100.0%
H
0.6
9035.3
|
L
H
0.6
66943.3
|
| Kiniksa Pharma Ltd (Class A) |
|
5,971.2
|
76.5
|
L
 0.6%
H
75
77.8
|
L
 3.0%
H
71.4
78.8
|
L
 17.1%
H
60.1
82.9
|
L
 30.6%
H
46.1
82.9
|
L
 138.0%
H
32
82.9
|
L
 337.8%
H
14.1
82.9
|
L
 491.0%
H
7.4
82.9
|
L
H
5.0
82.9
|
| Kiora Pharma Inc |
|
11.4
|
2.6
|
L
 -2.3%
H
2.6
2.7
|
L
 0.8%
H
2.4
2.7
|
L
 1.2%
H
2.3
2.7
|
L
 5.3%
H
2.3
2.9
|
L
 9.3%
H
1.8
3.0
|
L
 360.7%
H
0.4
5.6
|
L
 -97.2%
H
0.4
93.6
|
L
 -99.8%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
44.4
|
2.0
|
L
 -7.6%
H
1.9
2.2
|
L
 2.1%
H
1.8
2.2
|
L
 -80.8%
H
1.8
10.6
|
L
 -77.3%
H
1.8
10.9
|
L
 -50.3%
H
1.8
11.0
|
L
 -91.9%
H
0.6
29.3
|
L
 -97.7%
H
0.6
221.0
|
L
 -98.1%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
212.0
|
10.7
|
L
 -4.1%
H
10.5
11.2
|
L
 6.2%
H
9.7
11.3
|
L
 -11.1%
H
9.7
12.2
|
L
 -11.4%
H
9.7
12.2
|
L
 -22.1%
H
9.7
22.6
|
L
 -70.6%
H
9.1
73
|
L
 -69.2%
H
9.1
73
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
15.7
|
0.5
|
L
 -7.8%
H
0.5
0.5
|
L
 2.2%
H
0.4
0.5
|
L
 -6%
H
0.4
0.5
|
L
 -41.3%
H
0.4
0.8
|
L
 -30.9%
H
0.3
2.1
|
L
 -24.2%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Lexaria Bioscience Corp |
|
9.1
|
5.5
|
L
 4.2%
H
5.3
5.5
|
L
 -6.3%
H
4.2
6.1
|
L
 -40.5%
H
4.2
10.2
|
L
 -40%
H
4.2
10.8
|
L
 -56.7%
H
4.2
23.3
|
L
 -63.2%
H
4.2
102.8
|
L
 -93.8%
H
4.2
108
|
L
 -90.6%
H
4.2
1143
|
| Lifecore Biomedical Inc |
|
176.4
|
4.7
|
L
 -7.0%
H
4.7
5
|
L
 5.4%
H
4.2
5.0
|
L
 -1.9%
H
4.2
5.3
|
L
 -2.7%
H
4.2
6.0
|
L
 -35.6%
H
3.6
9.0
|
L
 -55.0%
H
3.6
10.6
|
L
 -57.6%
H
1.5
12.0
|
L
 -61.8%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
6,416.7
|
295.7
|
L
 0.9%
H
288.5
299.4
|
L
 2.8%
H
283.8
317.5
|
L
 -8.3%
H
283.8
322.8
|
L
 33.6%
H
205.2
326.6
|
L
 97.1%
H
137.1
326.6
|
L
 318.1%
H
49.3
326.6
|
L
 316.8%
H
46.8
326.6
|
L
 296.4%
H
36.9
326.6
|
| Atyr Pharma Inc |
|
52.0
|
0.5
|
L
 3.9%
H
0.5
0.5
|
L
 8.2%
H
0.5
0.5
|
L
 -8.6%
H
0.5
0.6
|
L
 -44.2%
H
0.4
1.0
|
L
 -90%
H
0.4
6.5
|
L
 -73.0%
H
0.4
7.3
|
L
 -88.9%
H
0.4
13.1
|
L
 -98.8%
H
0.4
90.9
|
| Lipocine Inc |
|
17.3
|
2.1
|
L
 -1.4%
H
2.1
2.2
|
L
 -0.9%
H
2.0
2.3
|
L
 -15.0%
H
2.0
2.5
|
L
 -11.4%
H
1.9
2.7
|
L
 -28.3%
H
1.8
12.4
|
L
 -58.7%
H
1.8
12.4
|
L
 -91.5%
H
1.8
32.1
|
L
 -97.1%
H
1.8
100.3
|
| Liquidia Corp |
|
8,095.1
|
91.0
|
L
 0.9%
H
87.6
92.4
|
L
 8.2%
H
78.1
92.4
|
L
 11.8%
H
69.7
92.4
|
L
 115.2%
H
39.6
92.4
|
L
 345.1%
H
19.9
92.4
|
L
 1089.9%
H
5.7
92.4
|
L
 3724.8%
H
2.3
92.4
|
L
H
2.3
92.4
|
| Lisata Therapeutics Inc |
|
9.8
|
1.1
|
L
 2.8%
H
1.0
1.1
|
L
 10.1%
H
1.0
1.2
|
L
 -66.4%
H
1.0
3.9
|
L
 -65.4%
H
1.0
4.0
|
L
 -58.1%
H
1.0
5.1
|
L
 -60.1%
H
1.0
5.1
|
L
 -94.5%
H
1.0
20.1
|
L
 -98.8%
H
1.0
174.8
|
| Lantern Pharma Inc |
|
35.9
|
2.8
|
L
 -1.8%
H
2.7
2.9
|
L
 6.8%
H
2.6
2.9
|
L
 -16.1%
H
2.5
3.8
|
L
 33.8%
H
2
4.3
|
L
 -43.7%
H
1.1
5.0
|
L
 -39.8%
H
1.1
12.0
|
L
 -79.7%
H
1.1
14.8
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
1,067.9
|
2.4
|
L
 -2.8%
H
2.4
2.5
|
L
 3.9%
H
2.0
2.5
|
L
 6.7%
H
2.0
2.5
|
L
 20%
H
1.8
2.7
|
L
 122.2%
H
1.0
2.7
|
L
 38.7%
H
0.3
3.7
|
L
 -35.7%
H
0.3
6.3
|
L
 -85.2%
H
0.3
19.6
|
| Legend Biotech Corp (ADR) |
|
3,996.5
|
20.7
|
L
 -0.4%
H
20.2
21
|
L
 11.4%
H
18.4
21
|
L
 -24.5%
H
18.3
27.5
|
L
 -26.5%
H
18.3
37.5
|
L
 -44.2%
H
16.2
38.4
|
L
 -70.5%
H
16.2
72.6
|
L
 -51.4%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
4.5
|
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 3.5%
H
0.5
0.7
|
L
 -20.3%
H
0.5
0.7
|
L
 -15.7%
H
0.5
0.9
|
L
 -64.5%
H
0.5
1.9
|
L
 -99.8%
H
0.1
255
|
L
 -100.0%
H
0.1
2317.5
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
3.1
|
0.4
|
L
 4.9%
H
0.4
0.5
|
L
 7.5%
H
0.2
0.5
|
L
 -82.4%
H
0.2
2.4
|
L
 -82.6%
H
0.2
3.7
|
L
 -97.5%
H
0.2
17.4
|
L
 -99.8%
H
0.2
3318.8
|
L
 -100.0%
H
0.2
3318.8
|
L
 -100.0%
H
0.2
15390
|
| Madrigal Pharma Inc |
|
11,906.5
|
515.3
|
L
 1.0%
H
501.2
517.5
|
L
 10.3%
H
461.3
524.5
|
L
 -8.0%
H
447.0
566.2
|
L
 1.0%
H
445.2
569.4
|
L
 49.1%
H
342.7
615
|
L
 205.4%
H
119.8
615
|
L
 489.8%
H
52.3
615
|
L
 6618.9%
H
7.3
615
|
| MediWound Ltd |
|
177.7
|
13.8
|
L
 -3.9%
H
13.8
14.5
|
L
 -2.1%
H
13.8
14.6
|
L
 -6.0%
H
13.8
14.9
|
L
 -16.5%
H
13.5
17.1
|
L
 -25.8%
H
13.5
20.3
|
L
 53.5%
H
7.1
24
|
L
 -48.4%
H
7.1
28.1
|
L
 -71.8%
H
7.1
60.1
|
| MEI Pharma Inc |
|
29.6
|
0.9
|
L
 -4.4%
H
0.9
0.9
|
L
 -9.4%
H
0.9
1.0
|
L
 -12.1%
H
0.9
1.1
|
L
 -28.7%
H
0.7
1.3
|
L
 -83.2%
H
0.7
5.6
|
L
 -87.4%
H
0.7
9
|
L
 -98.4%
H
0.7
71
|
L
 -97.8%
H
0.7
102.8
|
| Macrogenics Inc |
|
259.3
|
4.1
|
L
 1.0%
H
4.0
4.1
|
L
 10.6%
H
3.7
4.1
|
L
 -10.7%
H
3.4
4.6
|
L
 36%
H
2.9
5.1
|
L
 164.9%
H
1.3
5.1
|
L
 -18.1%
H
1.0
21.9
|
L
 -83.3%
H
1.0
28.1
|
L
 -87.0%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
10.3
|
0.6
|
L
 22.5%
H
0.5
0.6
|
L
 7.1%
H
0.4
0.6
|
L
 62.2%
H
0.3
1.3
|
L
 46.3%
H
0.3
1.3
|
L
 -67.7%
H
0.2
2.8
|
L
 -55.6%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Mirum Pharma Inc |
|
6,018.8
|
98.7
|
L
 -1.9%
H
97.4
100.6
|
L
 -6.8%
H
88.9
107
|
L
 -22.7%
H
88.9
127.5
|
L
 -7.9%
H
88.9
130
|
L
 64.6%
H
58.5
130
|
L
 282.7%
H
23.1
130
|
L
 592.6%
H
12.8
130
|
L
H
6.5
130
|
| Milestone Pharma Inc |
|
156.9
|
1.3
|
L
 3.3%
H
1.2
1.3
|
L
 13.5%
H
1.1
1.3
|
L
 -3.8%
H
1.0
1.3
|
L
 -34.4%
H
1.0
2.0
|
L
 -16%
H
1
3.1
|
L
 -59.6%
H
0.6
3.5
|
L
 -76.6%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,474.1
|
17.3
|
L
 -5.1%
H
16.5
17.8
|
L
 -6.0%
H
16.5
18.6
|
L
 -13.1%
H
16.5
21.3
|
L
 1.6%
H
15.8
23.3
|
L
 -66.9%
H
6.0
62.8
|
L
 -68.0%
H
6.0
65.0
|
L
 74.2%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
1,263.7
|
3.9
|
L
 -4.4%
H
3.9
4.1
|
L
 0.5%
H
3.7
4.2
|
L
 -5.1%
H
3.7
4.2
|
L
 11.7%
H
2.9
4.6
|
L
 11.7%
H
2.2
6.5
|
L
 -26.4%
H
2.2
7.6
|
L
 -1.3%
H
2.2
7.6
|
L
 -14.6%
H
0.7
7.6
|
| Mind Medicine Inc |
|
5,993.4
|
45.2
|
L
 -2.2%
H
43.5
46.0
|
L
 3.8%
H
41.5
49.7
|
L
 -6.8%
H
40.3
49.7
|
L
 104.8%
H
19.3
49.7
|
L
 358.4%
H
8.7
49.7
|
L
 980.1%
H
2.4
49.7
|
L
 -1.0%
H
2.1
49.7
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
65.0
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -0.8%
H
1.3
1.4
|
L
 -4.4%
H
1.3
1.4
|
L
 -5.7%
H
1.2
1.6
|
L
 -2.2%
H
1.2
2.0
|
L
 -44.1%
H
1.1
2.6
|
L
 -62.6%
H
1.1
4.7
|
L
 -80.4%
H
1.1
14.5
|
| TNF Pharma Inc |
|
22.1
|
2.8
|
L
 -3.4%
H
2.8
3.0
|
L
 8.1%
H
2.6
3.1
|
L
 -24.2%
H
2.5
3.7
|
L
 -25.2%
H
2.5
5.5
|
L
 -70.9%
H
2.5
12.2
|
L
 -99.9%
H
2.5
4410
|
L
 -100.0%
H
2.5
29850
|
L
 -100.0%
H
2.5
29850
|
| NewAmsterdam Pharma Co NV |
|
3,344.7
|
28.0
|
L
 0.1%
H
27.4
29.0
|
L
 0.7%
H
25.7
29.0
|
L
 -22.1%
H
25.7
36.2
|
L
 -27.8%
H
25.7
42.2
|
L
 10.6%
H
23.1
42.2
|
L
 161.5%
H
5.6
42.2
|
L
 187.9%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Minerva Neurosciences Inc |
|
215.2
|
4.6
|
L
 8.2%
H
4.2
4.7
|
L
 16.1%
H
4.0
4.7
|
L
 -2.1%
H
3.9
4.9
|
L
 -21.4%
H
3.9
6.1
|
L
 162.5%
H
1.8
12.5
|
L
 -49.4%
H
1.2
13.5
|
L
 -64.1%
H
1.2
17.0
|
L
 -95.0%
H
1.2
121.7
|
| Nektar Therapeutics |
|
2,529.2
|
74.9
|
L
 -2.1%
H
74.3
76.4
|
L
 5.9%
H
67.1
77
|
L
 2.7%
H
64.2
77
|
L
 -8.6%
H
54.1
81.0
|
L
 224.6%
H
22.3
109
|
L
 448.0%
H
6.2
109
|
L
 -67.8%
H
6.2
290.6
|
L
 -71.3%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
17.5
|
3.3
|
L
 -1.8%
H
3.2
3.3
|
L
 -6.9%
H
3.2
3.8
|
L
 -21.3%
H
3.2
4.3
|
L
 -3.3%
H
2.8
4.6
|
L
 -84.8%
H
1.8
28.0
|
L
 -99.1%
H
1.2
482
|
L
 -99.7%
H
1.2
1240
|
L
H
1.2
2940
|
| 9 Meters Biopharma Inc |
|
-
|
9.8
|
L
 -0.3%
H
9.6
9.8
|
L
 7.9%
H
9.1
9.9
|
L
 6.6%
H
8.5
9.9
|
L
 10.9%
H
8.5
9.9
|
L
 47.4%
H
6.4
9.9
|
L
 48850%
H
0.0
9.9
|
L
 -54.3%
H
0.0
29.2
|
L
 -98.4%
H
0.0
1010
|
| NeuroSense Therapeutics Ltd |
|
17.3
|
0.5
|
L
 -4%
H
0.5
0.5
|
L
 4.4%
H
0.4
0.6
|
L
 -33.3%
H
0.4
0.7
|
L
 -45.5%
H
0.4
1.0
|
L
 -61.9%
H
0.4
2.0
|
L
 -47.8%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
143.4
|
3.4
|
L
 -6.4%
H
3.3
3.6
|
L
 6.4%
H
2.9
4.2
|
L
 -18.5%
H
2.8
4.6
|
L
 8.8%
H
2.7
5.1
|
L
 32.9%
H
1.6
5.1
|
L
 8.4%
H
1.1
54
|
L
 -97.9%
H
1.1
197.5
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
615.1
|
18.9
|
L
 -0.4%
H
18.3
18.9
|
L
 -12.3%
H
17.9
22.9
|
L
 -0.6%
H
17.9
23.1
|
L
 62.1%
H
9.2
29.3
|
L
 214.7%
H
5.6
29.3
|
L
 26.4%
H
4.4
29.3
|
L
H
3.1
29.3
|
L
H
3.1
29.3
|
| Nextcure Inc |
|
31.3
|
6.8
|
L
 17.1%
H
5.9
7.2
|
L
 65.2%
H
4.0
7.2
|
L
 242%
H
1.7
9.9
|
L
 -29.9%
H
1.6
11.1
|
L
 40.5%
H
1.6
15.7
|
L
 -66.3%
H
1.6
30.8
|
L
 -92.3%
H
1.6
110.2
|
L
H
1.6
1308
|
| Nanobiotix (ADR) |
|
1,838.1
|
36.2
|
L
 -5.3%
H
35.4
38.1
|
L
 -5.7%
H
35.4
41.2
|
L
 -7.1%
H
35
42.5
|
L
 -20.5%
H
31.7
57.1
|
L
 390.2%
H
7.0
57.1
|
L
 363.3%
H
2.8
57.1
|
L
 173.9%
H
1.8
57.1
|
L
H
1.8
57.1
|
| Ocugen Inc |
|
444.2
|
1.3
|
L
 2.3%
H
1.3
1.3
|
L
 6.5%
H
1.2
1.3
|
L
 -10.9%
H
1.2
1.5
|
L
 -13.3%
H
1.2
1.7
|
L
 31%
H
1.0
2.7
|
L
 167.3%
H
0.3
2.7
|
L
 -83.9%
H
0.3
17.7
|
L
 -98.9%
H
0.2
268.2
|
| Ocular Therapeutix Inc |
|
2,029.3
|
9.2
|
L
 0.5%
H
9.0
9.3
|
L
 13.1%
H
8.2
9.3
|
L
 -12.3%
H
8.2
10.5
|
L
 -4.3%
H
7.9
10.9
|
L
 -24.3%
H
6.2
16.4
|
L
 136.3%
H
2
16.4
|
L
 -13.9%
H
2
16.4
|
L
 52.0%
H
2
24.3
|
| Opus Genetics Inc |
|
302.5
|
3.7
|
L
H
3.6
3.8
|
L
 -1.4%
H
3.5
4.0
|
L
 -9.0%
H
2.8
4.0
|
L
 -26.7%
H
2.8
5.2
|
L
 242.1%
H
1.0
5.8
|
L
 -10.9%
H
0.7
5.8
|
L
 -25.3%
H
0.7
6.6
|
L
 -97.1%
H
0.7
340.8
|
| Olema Pharma Inc |
|
1,042.9
|
11.9
|
L
 -0.9%
H
11.7
12.2
|
L
 4.3%
H
11.0
12.2
|
L
 -2.8%
H
10.7
12.5
|
L
 -19.9%
H
9.1
15.6
|
L
 157.3%
H
4.5
36.3
|
L
 12.6%
H
2.9
36.3
|
L
 -54.6%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
985.8
|
13.6
|
L
 2.8%
H
13
13.6
|
L
 15.0%
H
11.9
13.6
|
L
 32.6%
H
9.1
13.6
|
L
 -3.6%
H
6.7
14.9
|
L
 235.5%
H
3.9
17.7
|
L
 214.5%
H
0.9
17.7
|
L
 -6.3%
H
0.9
17.7
|
L
 1.8%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
1,411.7
|
13.6
|
L
 0.9%
H
13.1
13.8
|
L
 23.0%
H
10.5
14.1
|
L
 24.5%
H
10.3
14.1
|
L
 53.9%
H
7.3
14.1
|
L
 47.4%
H
7.2
14.9
|
L
 77.6%
H
3.9
16.7
|
L
 -17.0%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
174.7
|
4.2
|
L
 -2.3%
H
4.2
4.4
|
L
 3.2%
H
4.1
4.5
|
L
 0.5%
H
3.9
4.5
|
L
 2.7%
H
3.6
5.2
|
L
 101.0%
H
2.0
5.2
|
L
 32.5%
H
1.7
5.2
|
L
 -80.1%
H
1.7
31.5
|
L
 -46.7%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
215.0
|
1.2
|
L
 12.8%
H
1
1.2
|
L
 17.4%
H
0.8
1.2
|
L
 -31.6%
H
0.8
1.8
|
L
 422.7%
H
0.2
1.9
|
L
 -39.5%
H
0.2
3.0
|
L
 -99.8%
H
0.2
680
|
L
 -99.9%
H
0.2
1146
|
L
 -100.0%
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
489.0
|
2.6
|
L
 -0.4%
H
2.5
2.6
|
L
 18.0%
H
2.2
2.7
|
L
 0.8%
H
2.2
2.7
|
L
 -6.4%
H
2.2
2.9
|
L
 403.9%
H
0.5
3.1
|
L
 -20.6%
H
0.2
4.1
|
L
 -29.9%
H
0.2
4.2
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,385.3
|
34.2
|
L
 -0.4%
H
32.9
34.9
|
L
 -6%
H
32.9
37.4
|
L
 5.5%
H
30.6
37.9
|
L
 -14.6%
H
28.3
39.9
|
L
 21.5%
H
27.8
60.1
|
L
 125.1%
H
9.4
60.1
|
L
 42.4%
H
9.4
60.1
|
L
 62.3%
H
9.4
60.1
|
| Palisade Bio Inc |
|
364.9
|
2.1
|
L
 -0.5%
H
2.0
2.1
|
L
 10.5%
H
1.9
2.2
|
L
 6.6%
H
1.8
2.2
|
L
 16.7%
H
1.6
2.3
|
L
 165.8%
H
0.5
2.9
|
L
 -80.7%
H
0.4
29.0
|
L
 -99.9%
H
0.4
2400
|
L
 -100.0%
H
0.4
594000
|
| Puma biotech Inc |
|
442.3
|
8.7
|
L
 -2.5%
H
8.6
9.0
|
L
 9.6%
H
7.4
9.4
|
L
 10%
H
7.4
9.4
|
L
 16.0%
H
6.6
9.4
|
L
 135.5%
H
3.7
9.4
|
L
 113.0%
H
2.1
9.4
|
L
 24.9%
H
1.6
9.4
|
L
 -81.3%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
973.8
|
24.4
|
L
 -2.4%
H
24.2
25.3
|
L
 -7.5%
H
24.2
27.7
|
L
 -4.2%
H
24.2
27.7
|
L
 5.5%
H
21.9
27.7
|
L
 -3.0%
H
18.8
27.7
|
L
 -35.8%
H
11.2
39.2
|
L
 -59.6%
H
11.2
82.2
|
L
 -46.2%
H
11.2
82.2
|
| Processa Pharma Inc |
|
8.7
|
2.6
|
L
 1.6%
H
2.6
2.8
|
L
 21.4%
H
2.1
2.8
|
L
 32.5%
H
1.8
3.1
|
L
 -4.4%
H
1.7
3.4
|
L
 -55%
H
1.7
14.3
|
L
 -98.6%
H
1.7
450
|
L
 -99.9%
H
1.7
4495.5
|
L
 -100.0%
H
1.7
17937.5
|
| PDS biotech Corp |
|
40.8
|
0.7
|
L
 -6.4%
H
0.7
0.8
|
L
 5.8%
H
0.7
0.8
|
L
 -7.6%
H
0.7
0.8
|
L
 -41.6%
H
0.7
1.6
|
L
 -34.2%
H
0.5
1.6
|
L
 -86.3%
H
0.5
6.9
|
L
 -93.7%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| Phathom Pharma Inc |
|
693.3
|
8.6
|
L
 0.2%
H
8.4
8.9
|
L
 -2.1%
H
8.2
9.2
|
L
 -29.5%
H
8.2
12.6
|
L
 -29.5%
H
8.2
13.4
|
L
 -12.0%
H
8.2
18.3
|
L
 -43.4%
H
2.2
19.7
|
L
 -73.3%
H
2.2
37.2
|
L
H
2.2
64.5
|
| Praxis Precision Medicines Inc |
|
10,230.4
|
367.0
|
L
 1.7%
H
354.7
368.3
|
L
 19.2%
H
292.9
382.5
|
L
 10.2%
H
287.9
382.5
|
L
 11.2%
H
238.8
382.5
|
L
 698.8%
H
37.2
382.5
|
L
 2422.1%
H
13
382.5
|
L
 67.1%
H
11.9
382.5
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
3.2
|
1.1
|
L
 1.0%
H
1.0
1.2
|
L
 5%
H
1.0
1.2
|
L
 -26.1%
H
1.0
1.4
|
L
 -45.9%
H
1.0
5.4
|
L
 -21.1%
H
0.6
5.4
|
L
 -97.6%
H
0.2
43.6
|
L
 -99.4%
H
0.2
208.2
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
255.4
|
1.8
|
L
 -3.7%
H
1.8
1.9
|
L
 5.2%
H
1.7
2
|
L
 2.8%
H
1.6
2
|
L
 14.6%
H
1.4
2
|
L
 -16.6%
H
1.3
3.1
|
L
 22.3%
H
1.1
4.6
|
L
 -71.1%
H
0.5
9.1
|
L
 -65.3%
H
0.5
24
|
| Cerenome Inc |
|
26.4
|
3.8
|
L
 0.3%
H
3.8
4.0
|
L
 -0.8%
H
3.3
4.2
|
L
 -4%
H
3.3
4.4
|
L
 -37.3%
H
3.3
7.3
|
L
 -80.7%
H
2.9
23.4
|
L
 -94.7%
H
2.9
80.3
|
L
 -99.5%
H
2.9
870
|
L
 -100.0%
H
2.9
429375
|
| PTC Therapeutics Inc |
|
6,228.7
|
74.6
|
L
 1.8%
H
72.5
74.8
|
L
 9.7%
H
66.1
74.8
|
L
 -16.7%
H
64.6
89.7
|
L
 1.3%
H
64.6
90.9
|
L
 64.5%
H
43.2
90.9
|
L
 87.3%
H
17.5
90.9
|
L
 87.7%
H
17.5
90.9
|
L
 856.8%
H
4.0
90.9
|
| Protagonist Therapeutics Inc |
|
9,706.2
|
150
|
L
 2.8%
H
147.4
151.6
|
L
 9.8%
H
131.7
151.6
|
L
 9.0%
H
125.3
151.6
|
L
 51.0%
H
92.8
151.6
|
L
 193.7%
H
50.6
151.6
|
L
 722.8%
H
13.7
151.6
|
L
 205.7%
H
6.9
151.6
|
L
H
4.5
151.6
|
| Pulmatrix Inc |
|
5.7
|
1.6
|
L
 -5.4%
H
1.6
1.6
|
L
 -9.8%
H
1.6
1.8
|
L
 -12.8%
H
1.6
1.8
|
L
 20.8%
H
1.2
1.9
|
L
 -69.0%
H
1.2
5.5
|
L
 -40.3%
H
1.2
10.4
|
L
 -90.4%
H
1.2
20.8
|
L
 -99.6%
H
1.2
1396
|
| Polypid Ltd |
|
91.5
|
4.8
|
L
 -1.5%
H
4.7
4.9
|
L
 11.2%
H
4.0
5.0
|
L
 -12.0%
H
3.7
5.7
|
L
 8.9%
H
3.7
5.7
|
L
 48.1%
H
3.1
5.7
|
L
 -53.2%
H
2.3
11.1
|
L
 -98.2%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
242.7
|
3.8
|
L
 2.7%
H
3.7
4.0
|
L
 44.5%
H
2.7
4.0
|
L
 45.1%
H
2.1
4.0
|
L
 39.8%
H
1.5
4.0
|
L
 261.3%
H
1.0
5.6
|
L
 58.3%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
803.3
|
11.4
|
L
 3.7%
H
10.5
11.7
|
L
 12.6%
H
9.8
11.7
|
L
 -19.2%
H
9.6
14.3
|
L
 -12.6%
H
9.6
14.8
|
L
 -14.2%
H
9.6
21.3
|
L
 -7.5%
H
6.7
21.3
|
L
 7.8%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
2.4
|
1.5
|
L
 4.9%
H
1.3
1.7
|
L
 7.1%
H
1.2
1.7
|
L
 -8.5%
H
1.2
1.7
|
L
 -63.6%
H
1.2
4.2
|
L
 -93.0%
H
1.2
24
|
L
 -100.0%
H
1.2
7200
|
L
 -100.0%
H
1.2
20720
|
L
 -100.0%
H
1.2
182000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
120.2
|
0.3
|
L
H
0.3
0.3
|
L
 7.1%
H
0.3
0.3
|
L
 -11.8%
H
0.3
0.4
|
L
 3.5%
H
0.3
0.5
|
L
 -96.1%
H
0.3
11.8
|
L
 -92.4%
H
0.3
17.2
|
L
 -98.6%
H
0.3
22.5
|
L
H
0.3
110
|
| Quoin Pharma Ltd (ADR) |
|
10.8
|
5.4
|
L
 11.9%
H
4.7
5.4
|
L
 20.5%
H
4.3
5.4
|
L
 14.8%
H
4.0
5.4
|
L
 -9.6%
H
3.3
6.4
|
L
 -25.0%
H
3.3
41.8
|
L
 -99.9%
H
3.3
4732
|
L
 -100.0%
H
3.3
3003840
|
L
 -100.0%
H
3.3
3003840
|
| Ultragenyx Pharmaceutical Inc |
|
2,642.2
|
26.8
|
L
 3.4%
H
25.5
27.1
|
L
 7.6%
H
24.0
28.5
|
L
 -22.6%
H
24.0
34.8
|
L
 2.6%
H
21.3
36.6
|
L
 -2.7%
H
18.3
39.9
|
L
 -27.2%
H
18.3
60.4
|
L
 -70.2%
H
18.3
104.4
|
L
 -58.8%
H
18.3
179.7
|
| Regeneron Pharma |
|
83,192.8
|
808.1
|
L
 3.0%
H
775.8
809.1
|
L
 6.0%
H
747
809.1
|
L
 21.0%
H
637.8
809.1
|
L
 13.0%
H
591.5
809.1
|
L
 43.5%
H
541
821.1
|
L
 2.9%
H
476.5
1211.2
|
L
 31.6%
H
476.5
1211.2
|
L
 92.7%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
2,610.9
|
5.3
|
L
 -2.4%
H
5.2
5.7
|
L
 -14.6%
H
5.2
6.8
|
L
 -13.0%
H
4.5
6.8
|
L
 -82.0%
H
4.5
30
|
L
 -62.2%
H
4.5
69
|
L
 1452.9%
H
0.1
83.6
|
L
 2195.7%
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
9,208.6
|
163.2
|
L
 -0.5%
H
161.0
166.4
|
L
 15.7%
H
140.5
166.4
|
L
 13.4%
H
129
166.4
|
L
 32.2%
H
101.0
166.4
|
L
 46.4%
H
101.0
175.8
|
L
 -5.6%
H
101.0
211.1
|
L
 -36.1%
H
101.0
327.3
|
L
 445.7%
H
26.2
327.3
|
| Regenxbio Inc |
|
687.9
|
10.4
|
L
 -2.8%
H
10.3
10.9
|
L
 7.5%
H
9.3
11.5
|
L
 -33.4%
H
8.4
15.7
|
L
 -1.2%
H
5.5
15.9
|
L
 32.7%
H
5.5
16.2
|
L
 -42.4%
H
5.0
28.8
|
L
 -67.9%
H
5.0
46.5
|
L
 -0.2%
H
5.0
85.1
|
| Rigel Pharma |
|
778.2
|
41.7
|
L
 3.7%
H
39.9
41.8
|
L
 13.2%
H
36.4
43.5
|
L
 -4.8%
H
35.0
44.0
|
L
 60.0%
H
25.5
44.0
|
L
 31.4%
H
25.0
52.2
|
L
 3687.3%
H
0.7
52.2
|
L
 987.7%
H
0.6
52.2
|
L
 1312.2%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
484.3
|
4.5
|
L
 -8.1%
H
4.5
4.9
|
L
 -14.5%
H
4.5
5.6
|
L
 -30.3%
H
4.5
6.6
|
L
 -38.0%
H
4.5
7.7
|
L
 669.5%
H
0.6
8
|
L
 66.9%
H
0.2
8
|
L
 -80.0%
H
0.2
38.7
|
L
 -19.5%
H
0.2
54
|
| RenovoRx Inc |
|
52.3
|
1.2
|
L
 3.6%
H
1.1
1.2
|
L
 20.8%
H
1.0
1.2
|
L
 23.4%
H
0.8
1.2
|
L
 34.9%
H
0.8
1.2
|
L
 1.8%
H
0.7
1.5
|
L
 -42%
H
0.6
2.4
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
25,844.7
|
35.8
|
L
 -1.5%
H
35.7
36.8
|
L
 5.5%
H
32.5
36.8
|
L
 -2.8%
H
32.5
37
|
L
 25.3%
H
27.9
37
|
L
 211.4%
H
10.9
37
|
L
 217.2%
H
8.2
37
|
L
 261.4%
H
2.5
37
|
L
H
2.5
37
|
| Royalty Pharma PLC (Class A) |
|
25,812.7
|
58.0
|
L
 2.1%
H
56.5
58.0
|
L
 -0.8%
H
56.4
59.6
|
L
 0.0%
H
55.0
60.4
|
L
 14.1%
H
50.5
60.4
|
L
 54.3%
H
34.1
60.4
|
L
 89.8%
H
24.1
60.4
|
L
 57.6%
H
24.1
60.4
|
L
H
24.1
60.4
|
| Rhythm Pharma Inc |
|
7,951.0
|
115.5
|
L
 -0.1%
H
113.7
116.9
|
L
 16.4%
H
97.6
116.9
|
L
H
97.6
116.9
|
L
 22.6%
H
82.9
116.9
|
L
 25.6%
H
74.5
122.2
|
L
 357.9%
H
21.0
122.2
|
L
 741.7%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
450.6
|
4.7
|
L
 -0.2%
H
4.6
4.8
|
L
 -0.9%
H
4.5
5.3
|
L
 -8.8%
H
4.1
5.4
|
L
 45.8%
H
2.8
5.4
|
L
 -19.5%
H
1.1
11.5
|
L
 222.8%
H
0.7
11.5
|
L
 -56.1%
H
0.7
11.8
|
L
 -89.0%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
3.5
|
0.6
|
L
 -3.3%
H
0.6
0.7
|
L
 -10.8%
H
0.6
0.7
|
L
 -17.1%
H
0.6
0.8
|
L
 -42.6%
H
0.6
1.1
|
L
 -50%
H
0.6
2.8
|
L
 -97.5%
H
0.6
82
|
L
 -100.0%
H
0.6
11180
|
L
 -100.0%
H
0.6
15989.9
|
| Sunshine Biopharma Inc |
|
2.9
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 4.3%
H
1.1
1.5
|
L
 -43.0%
H
1.1
2.1
|
L
 -88.4%
H
1.1
23.2
|
L
 -91.3%
H
1.1
24.3
|
L
 -100.0%
H
1.1
12900
|
L
 -100.0%
H
1.1
596000
|
L
 -100.0%
H
1.1
45037037.0
|
| Scynexis Inc |
|
51.2
|
5.2
|
L
 -1.5%
H
5.1
5.3
|
L
 6.6%
H
4.4
5.5
|
L
 13.2%
H
3.5
5.5
|
L
 -29.6%
H
3.5
7.3
|
L
 -25.4%
H
3.5
10.5
|
L
 -78.0%
H
3.5
31.0
|
L
 -90.6%
H
3.5
64.8
|
L
 -96.8%
H
3.5
440.8
|
| Shuttle Pharma Holdings Inc |
|
2.4
|
4.1
|
L
 -6.7%
H
3.9
4.2
|
L
 7.1%
H
3.2
4.6
|
L
 24.1%
H
2.6
5.1
|
L
 489.9%
H
0.4
6.2
|
L
 19.0%
H
0.4
6.2
|
L
 -97.5%
H
0.4
176
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
210.2
|
2.9
|
L
 -3.9%
H
2.9
3.1
|
L
 -10.4%
H
2.9
3.3
|
L
 -16.3%
H
2.9
3.7
|
L
 -39.0%
H
2.9
4.9
|
L
 -67.3%
H
2.9
9.6
|
L
 -45.8%
H
2.9
12.8
|
L
 -53.8%
H
2.9
27.0
|
L
 27.4%
H
1.9
27.0
|
| SILO Pharma Inc |
|
4.7
|
3.8
|
L
 1.1%
H
3.7
3.9
|
L
 -9.8%
H
3.6
4.8
|
L
 -51.1%
H
3.6
6.3
|
L
 845%
H
0.3
8.0
|
L
 447.8%
H
0.2
8.0
|
L
 89%
H
0.2
8.0
|
L
 -60.2%
H
0.2
496
|
L
 -92.4%
H
0.2
496
|
| Sol-Gel Tech Ltd |
|
277.0
|
84.7
|
L
 -3.7%
H
83.8
90.7
|
L
 3.0%
H
81.1
90.7
|
L
 11.0%
H
72.3
93.7
|
L
 19.6%
H
62.5
93.7
|
L
 430.0%
H
14.8
98.0
|
L
 2581.6%
H
0.3
98.0
|
L
 739.8%
H
0.3
98.0
|
L
H
0.3
98.0
|
| SELLAS Life Sciences Grp Inc |
|
2,170.8
|
11.0
|
L
 -8.1%
H
10.9
12
|
L
 10.3%
H
9.8
12.2
|
L
 -18.3%
H
9.2
13.7
|
L
 120.4%
H
5.0
15.9
|
L
 598.7%
H
1.4
15.9
|
L
 603.2%
H
0.5
15.9
|
L
 14.4%
H
0.5
15.9
|
L
 -99.9%
H
0.5
13800
|
| Soligenix Inc |
|
5.6
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 2.7%
H
0.4
0.4
|
L
 2.7%
H
0.3
0.4
|
L
 31.0%
H
0.3
1.1
|
L
 -86.9%
H
0.3
6.2
|
L
 -95.6%
H
0.3
85.3
|
L
 -99.8%
H
0.3
295.2
|
L
 -100.0%
H
0.3
2040.1
|
| Sonoma Pharma Inc |
|
6.2
|
1.3
|
L
 -10.4%
H
1.2
1.4
|
L
 17.3%
H
1.1
1.5
|
L
 2.4%
H
1.1
1.5
|
L
 7.5%
H
1
1.5
|
L
 -57.8%
H
0.9
6.9
|
L
 27.7%
H
0.1
6.9
|
L
 -77.6%
H
0.1
13.4
|
L
 -96.3%
H
0.1
74.2
|
| SciSparc Ltd |
|
3.8
|
6.6
|
L
 -4.6%
H
6.5
7.1
|
L
 -7.2%
H
6.5
7.8
|
L
 21.3%
H
4.2
11.5
|
L
 5.8%
H
4
15.8
|
L
 -85.9%
H
3.0
80.1
|
L
 -99.7%
H
3.0
2687.6
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| ARS Pharma Inc |
|
586.9
|
5.9
|
L
 -4.1%
H
5.8
6.2
|
L
 15.2%
H
4.9
6.2
|
L
 -25%
H
4.9
8.1
|
L
 -32.4%
H
4.9
10.9
|
L
 -66.2%
H
4.9
17.5
|
L
 -14.2%
H
2.6
18.9
|
L
 -79.6%
H
2.6
31.7
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
35.1
|
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
 -2.8%
H
0.6
0.8
|
L
 -23.9%
H
0.6
1.0
|
L
 -53.3%
H
0.4
1.8
|
L
 -63.4%
H
0.4
5.3
|
L
 94.4%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,814.7
|
17.2
|
L
 2.4%
H
16.4
17.2
|
L
 15.6%
H
14.8
17.3
|
L
 -16.3%
H
14.8
20.5
|
L
 -13.9%
H
14.7
21.0
|
L
 -5.8%
H
14.7
25.3
|
L
 -83.4%
H
10.4
173.3
|
L
 -78.1%
H
10.4
173.3
|
L
 -35.3%
H
10.4
181.8
|
| Sutro Biopharma Inc |
|
423.0
|
25.5
|
L
 0.6%
H
24.9
26.3
|
L
 5.6%
H
23
26.4
|
L
 -14.9%
H
21.7
30.1
|
L
 -36.6%
H
21.7
43.9
|
L
 218.3%
H
7.2
43.9
|
L
 -39.5%
H
5.2
61.3
|
L
 -86.1%
H
5.2
237
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,738.0
|
47.1
|
L
 -1.2%
H
46.5
47.7
|
L
 5.5%
H
42.6
52.5
|
L
 -3.5%
H
42.6
52.5
|
L
 -8.7%
H
42.5
52.5
|
L
 14.2%
H
40.3
59.7
|
L
 54.2%
H
22
59.7
|
L
 82.9%
H
22
59.7
|
L
 103.1%
H
13.1
61.3
|
| Savara Inc |
|
1,174.2
|
5.7
|
L
 -1.7%
H
5.6
5.9
|
L
 5.0%
H
5.3
6.0
|
L
 -8.9%
H
5.2
6.3
|
L
 9.6%
H
4.7
6.5
|
L
 117.1%
H
2.4
7
|
L
 54.0%
H
1.9
7
|
L
 351.2%
H
1.0
7
|
L
 -76.7%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
1.9
|
3.6
|
L
 -1.4%
H
3.2
4.2
|
L
 -27.6%
H
3.2
10.4
|
L
 -98.2%
H
3.2
228
|
L
 -97.4%
H
3.2
234.2
|
L
 -100.0%
H
3.2
83760
|
L
 -100.0%
H
3.2
900000
|
L
 -100.0%
H
3.2
5472000
|
L
H
3.2
224449238.7
|
| Sanofi (ADR) |
|
104,184.1
|
43.5
|
L
 0.1%
H
43.3
43.7
|
L
 0.9%
H
42.5
43.9
|
L
 -1.0%
H
41.4
45.7
|
L
 0.4%
H
40.9
45.7
|
L
 -7.7%
H
40.9
52.7
|
L
 -18.3%
H
40.9
60.1
|
L
 -14.9%
H
36.9
60.1
|
L
 7.3%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
231.0
|
4.1
|
L
 -0.2%
H
4.1
4.2
|
L
 4.9%
H
3.9
4.2
|
L
 -2.1%
H
3.8
4.4
|
L
 -22.0%
H
3.6
5.5
|
L
 31.3%
H
3.0
7.8
|
L
 72.0%
H
1.0
10.5
|
L
 -47.2%
H
1.0
10.5
|
L
 -98.8%
H
1.0
458
|
| Tarsus Pharma Inc |
|
2,973.5
|
67.8
|
L
 4.6%
H
62.9
67.9
|
L
 14.8%
H
57.6
68
|
L
 5.6%
H
53.9
68
|
L
 10.7%
H
53.9
72.5
|
L
 41.6%
H
47.6
85.3
|
L
 292.6%
H
12.7
85.3
|
L
 177.7%
H
10.8
85.3
|
L
H
10.8
85.3
|
| Theravance Biopharma Inc |
|
876.4
|
16.9
|
L
 -0.1%
H
16.9
17.0
|
L
 0.3%
H
16.9
17.0
|
L
 -0.4%
H
16.8
17.0
|
L
 -0.6%
H
15.5
17.7
|
L
 46.8%
H
11.3
21.0
|
L
 65.8%
H
7.4
21.0
|
L
 30.1%
H
6.1
21.0
|
L
 -35.3%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
51.6
|
1.4
|
L
 -89.7%
H
1.3
1.8
|
L
 -89.9%
H
1.3
14.6
|
L
 -92.5%
H
1.3
18.3
|
L
 -88.2%
H
1.3
19.4
|
L
 -76.7%
H
1.3
19.4
|
L
 -94.4%
H
1.3
61.2
|
L
 -99.9%
H
1.3
3135.0
|
L
 -100.0%
H
1.3
84800
|
| TG Therapeutics Inc |
|
7,524.9
|
49.2
|
L
 -1.2%
H
48.5
50
|
L
 -5.5%
H
45.4
52.7
|
L
 -16.8%
H
45.4
59.0
|
L
 14.7%
H
36.5
59.3
|
L
 84.1%
H
25.3
59.3
|
L
 407.9%
H
6.5
59.3
|
L
 108.8%
H
3.5
59.3
|
L
 784.2%
H
3.3
59.3
|
| Alpha Teknova Inc |
|
360.8
|
6.7
|
L
 4.0%
H
6.3
6.9
|
L
 34.4%
H
4.9
6.9
|
L
 24.0%
H
4.7
6.9
|
L
 75.5%
H
3.4
6.9
|
L
 58.9%
H
1.9
6.9
|
L
 156.5%
H
1.2
10.4
|
L
 -68.3%
H
1.2
28.6
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
128.5
|
1.0
|
L
 1%
H
1.0
1.1
|
L
 -1.9%
H
0.9
1.1
|
L
 -19.8%
H
0.9
1.5
|
L
 -36.1%
H
0.9
1.9
|
L
 -54.1%
H
0.9
2.5
|
L
 60.3%
H
0.4
2.6
|
L
 -49.8%
H
0.4
2.6
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
200.7
|
12.6
|
L
 4.7%
H
11.1
13.9
|
L
 25.8%
H
10.0
13.9
|
L
 -3.4%
H
9.4
13.9
|
L
 -10.7%
H
9.4
15.9
|
L
 -72.9%
H
9.4
70.0
|
L
 -99.6%
H
0.2
3232
|
L
 -100.0%
H
0.2
521600
|
L
 -100.0%
H
0.2
1792000000
|
| Tenaya Therapeutics Inc |
|
165.9
|
0.7
|
L
 1.4%
H
0.7
0.8
|
L
H
0.7
0.8
|
L
 -12.9%
H
0.7
0.9
|
L
 -26%
H
0.7
1.2
|
L
 10.5%
H
0.5
2.4
|
L
 -82.3%
H
0.4
7.0
|
L
 -96.3%
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
16.6
|
1.0
|
L
 13.0%
H
0.9
1.1
|
L
 20.9%
H
0.9
1.1
|
L
 6.1%
H
0.8
1.1
|
L
 -47.7%
H
0.8
2.1
|
L
 -85.9%
H
0.8
12.2
|
L
 79.3%
H
0.2
12.2
|
L
 -92.9%
H
0.2
16.4
|
L
 -99.9%
H
0.2
2020.5
|
| Travere Therapeutics Inc |
|
5,739.6
|
60.9
|
L
 -0.7%
H
60.6
62.6
|
L
 9.0%
H
53.4
66.2
|
L
 4.1%
H
53
66.2
|
L
 42.9%
H
41.3
66.2
|
L
 259.5%
H
17.0
66.2
|
L
 299.3%
H
5.1
66.2
|
L
 329.1%
H
5.1
66.2
|
L
 233.1%
H
5.1
66.2
|
| TherapeuticsMD Inc |
|
24.0
|
2.1
|
L
H
2.1
2.1
|
L
 2.0%
H
2.0
2.1
|
L
 3.0%
H
1.9
2.1
|
L
 4.6%
H
1.8
2.4
|
L
 95.3%
H
1.0
3.0
|
L
 -48.4%
H
0.7
4.1
|
L
 -95.7%
H
0.7
48.0
|
L
 -99.5%
H
0.7
414.8
|
| Universe Pharma INC |
|
4.6
|
7.1
|
L
 27.5%
H
5.5
7.5
|
L
 124.4%
H
5.4
8.4
|
L
 32.8%
H
3.1
8.4
|
L
 153.2%
H
2.5
18.0
|
L
 97.5%
H
2
18.0
|
L
 -71.7%
H
0.1
64.8
|
L
 -82.1%
H
0.1
64.8
|
L
H
0.1
179.9
|
| Vericel Corp |
|
2,250.5
|
44.0
|
L
 -2.5%
H
43.2
44.8
|
L
 -4.4%
H
43.2
47.3
|
L
 -9.0%
H
43.2
49.3
|
L
 31.4%
H
32.0
49.3
|
L
 21.3%
H
29.0
49.3
|
L
 36.7%
H
29.0
63
|
L
 -11.0%
H
17.3
63
|
L
 1879.7%
H
2
68.9
|
| Veru Inc |
|
44.5
|
2.8
|
L
 18.9%
H
2.3
2.9
|
L
 23.7%
H
2.2
2.9
|
L
 -1.4%
H
2.2
2.9
|
L
 23.7%
H
2.1
7.3
|
L
 -25.7%
H
2.1
7.3
|
L
 -74.4%
H
2.1
19.2
|
L
 -96.1%
H
2.1
245.5
|
L
 -80.4%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
61.5
|
1.8
|
L
 1.7%
H
1.7
1.9
|
L
 11.6%
H
1.6
1.9
|
L
 29.8%
H
1.3
1.9
|
L
 10.9%
H
1.3
2.0
|
L
 -62.6%
H
1.3
9.5
|
L
 16.6%
H
0.1
29.3
|
L
 -66.2%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
4,017.5
|
34.4
|
L
 0.5%
H
33.8
34.7
|
L
 8.5%
H
31.3
34.7
|
L
 -16.3%
H
30.8
41.1
|
L
 9.9%
H
27.2
42.8
|
L
 -9.1%
H
23.0
43.2
|
L
 136.1%
H
8.3
99.4
|
L
 483.7%
H
2.0
99.4
|
L
 2509.1%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
303.5
|
5.0
|
L
 0.4%
H
4.8
5.1
|
L
 -1.6%
H
4.5
5.4
|
L
 -21.3%
H
4.5
6.4
|
L
 -20.1%
H
4.5
6.7
|
L
 19.5%
H
4.2
9.9
|
L
 -16.7%
H
3.3
9.9
|
L
 -68.9%
H
3.3
21.4
|
L
 -59.6%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
88.0
|
5.1
|
L
 0.8%
H
5.1
5.3
|
L
 -1.9%
H
4.7
5.9
|
L
 -21.6%
H
4.7
6.6
|
L
 -35.9%
H
4.7
8.2
|
L
 -19.4%
H
3.3
9.8
|
L
 -7.2%
H
0.4
11.4
|
L
 -52.7%
H
0.4
14.8
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
2,612.5
|
23.1
|
L
 -2.3%
H
22.8
23.6
|
L
 21.9%
H
18.4
23.6
|
L
 14.2%
H
17.5
23.6
|
L
 38.8%
H
15.5
23.6
|
L
 40.5%
H
13.2
34.3
|
L
 19.7%
H
9.9
34.3
|
L
 62.4%
H
9.5
39
|
L
 -80.7%
H
4.7
270
|
| Vertex Pharma |
|
132,790.7
|
523.9
|
L
 5.6%
H
519.8
546.2
|
L
 9.8%
H
465.5
546.2
|
L
 5.5%
H
465
546.2
|
L
 21.9%
H
420.0
546.2
|
L
 42.9%
H
362.5
546.2
|
L
 51.8%
H
340.8
546.2
|
L
 161.4%
H
176.4
546.2
|
L
 409.5%
H
71.5
546.2
|
| Viatris |
|
18,699.1
|
16.3
|
L
 -0.9%
H
16.1
16.7
|
L
 -7.3%
H
16.1
18.4
|
L
 -0.4%
H
16.0
18.4
|
L
 -5.2%
H
14.9
18.4
|
L
 67.8%
H
9.4
18.4
|
L
 44.6%
H
6.9
18.4
|
L
 7.8%
H
6.9
18.4
|
L
 -67.4%
H
6.9
49.9
|
| vTv Therapeutics Inc (Class A) |
|
135.1
|
34.3
|
L
 -3.1%
H
33.9
35.5
|
L
 6%
H
31.5
36.5
|
L
 2.5%
H
29.4
36.5
|
L
 11.8%
H
29.4
38.8
|
L
 144.9%
H
14
44
|
L
 5017.9%
H
0.4
44
|
L
 1676.7%
H
0.4
44
|
L
 523.5%
H
0.4
44
|
| Yarrow Bioscience Inc |
|
112.1
|
42.0
|
L
 1.3%
H
40.2
42.3
|
L
 19.9%
H
32.4
44.3
|
L
 24.9%
H
23.4
47.0
|
L
 27.0%
H
23.4
47.0
|
L
 135.1%
H
14.1
47.0
|
L
 -83.8%
H
14.1
318.5
|
L
 -98.3%
H
14.1
2619
|
L
H
14.1
143496
|
| Vaccitech PLC (ADR) |
|
21.6
|
0.6
|
L
 -6.7%
H
0.6
0.6
|
L
H
0.6
0.6
|
L
 -12.5%
H
0.5
0.7
|
L
 -16.4%
H
0.5
0.8
|
L
 -58.2%
H
0.5
1.8
|
L
 -74.5%
H
0.5
5.1
|
L
 -96.4%
H
0.5
16.5
|
L
H
0.5
18.0
|
| Xenetic Biosciences Inc |
|
7.1
|
3.1
|
L
 -2.5%
H
3.0
3.2
|
L
 21.7%
H
2.5
3.3
|
L
 11.2%
H
2.4
3.3
|
L
 0.7%
H
2.4
3.5
|
L
 11.6%
H
1.9
13.9
|
L
 -14.2%
H
1.9
13.9
|
L
 -91.1%
H
1.9
44.4
|
L
 -99.5%
H
1.9
1074
|
| Xenon Pharma Inc |
|
6,208.8
|
64.2
|
L
 1.4%
H
62.9
64.2
|
L
 2.5%
H
61.2
66.4
|
L
 -9.5%
H
61.2
71.0
|
L
 13.8%
H
50.9
72.7
|
L
 92.1%
H
32.8
72.7
|
L
 81.2%
H
26.7
72.7
|
L
 291.9%
H
14.7
72.7
|
L
 734.2%
H
2.1
72.7
|
| Xilio Therapeutics Inc |
|
60.5
|
9.2
|
L
 0.3%
H
8.8
9.3
|
L
 1.0%
H
8.8
9.6
|
L
H
8.3
9.6
|
L
 18.9%
H
7.5
9.9
|
L
 -0.9%
H
6.5
12.7
|
L
 -75.6%
H
6.5
40.9
|
L
H
6.5
391.3
|
L
H
6.5
391.3
|
| XORTX Therapeutics Inc |
|
3.7
|
2.2
|
L
 1.4%
H
2.1
2.2
|
L
 1.9%
H
2.0
2.3
|
L
 2.9%
H
2.0
2.3
|
L
 -22.6%
H
2.0
2.8
|
L
 -89.1%
H
1.7
35.3
|
L
 -98.5%
H
1.7
188.1
|
L
 -99.6%
H
1.7
1841.6
|
L
H
1.7
1841.6
|
| Zevra Therapeutics Inc |
|
681.7
|
11.5
|
L
 -0.7%
H
11.2
11.5
|
L
 20.7%
H
9.5
12.3
|
L
 -17.7%
H
9.1
14.0
|
L
 3.1%
H
9.1
15.0
|
L
 -4.5%
H
7.2
15.0
|
L
 131.9%
H
3.9
15.0
|
L
 12.2%
H
3.9
15.0
|
L
 -82.1%
H
1.9
134.4
|
| Zymeworks BC Inc |
|
1,714.4
|
24.2
|
L
 2.6%
H
23.5
24.2
|
L
 10.1%
H
21.5
24.8
|
L
 -10.8%
H
21.5
27.1
|
L
 1.1%
H
21.5
27.4
|
L
 101%
H
11.9
29.8
|
L
 213.8%
H
6.0
29.8
|
L
 -28.8%
H
4.1
37.2
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
591.0
|
9.6
|
L
 5.6%
H
8.8
9.6
|
L
 34.6%
H
6.5
9.6
|
L
 30.2%
H
6.5
9.6
|
L
 24.1%
H
6.2
9.6
|
L
 9.6%
H
4.5
10.1
|
L
 25.6%
H
1.7
20.7
|
L
 25.6%
H
1.7
20.7
|
L
 25.6%
H
1.7
20.7
|
| Neumora Therapeutics Inc |
|
300.2
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 0.6%
H
1.5
1.7
|
L
 -1.8%
H
1.5
1.7
|
L
 -11.5%
H
0.8
2.0
|
L
 11.0%
H
0.8
3.7
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Conduit Pharma Inc |
|
2.0
|
3.1
|
L
 -9.1%
H
3
3.5
|
L
 6.1%
H
2.8
3.7
|
L
 -24.2%
H
2.5
4.1
|
L
 -84.5%
H
2.5
28.9
|
L
 -99.9%
H
2.5
3700
|
L
 -100.0%
H
2.5
75000000
|
L
H
2.5
75000000
|
L
H
2.5
75000000
|
| Gyre Therapeutics Inc |
|
749.2
|
6.7
|
L
 0.8%
H
6.3
6.8
|
L
 16.9%
H
5.8
6.8
|
L
 -2.0%
H
5.6
6.9
|
L
 -10.0%
H
5.4
7.5
|
L
 -6.5%
H
5.4
9.4
|
L
 -10.4%
H
5.4
130.5
|
L
 -10.4%
H
5.4
130.5
|
L
 -10.4%
H
5.4
130.5
|
| Korro Bio Inc |
|
198.6
|
13.5
|
L
 1.8%
H
13
13.7
|
L
 30.1%
H
10.2
13.7
|
L
 -5.7%
H
9.8
14.7
|
L
 12.0%
H
9.1
15.6
|
L
 -15.7%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Barinthus Biotherapeutics PLC. (ADR) |
|
22.9
|
0.6
|
L
 -6.7%
H
0.6
0.6
|
L
H
0.6
0.6
|
L
 -12.5%
H
0.5
0.7
|
L
 -16.4%
H
0.5
0.8
|
L
 -58.2%
H
0.5
1.8
|
L
 -84.6%
H
0.5
5.1
|
L
 -84.6%
H
0.5
5.1
|
L
 -84.6%
H
0.5
5.1
|
| Spyre Therapeutics Inc |
|
9,287.3
|
105.3
|
L
 0.4%
H
103.3
107
|
L
 7.1%
H
92.7
108.1
|
L
 6.7%
H
92.4
108.1
|
L
 40.4%
H
64.7
108.1
|
L
 594.8%
H
14.5
108.1
|
L
H
8.8
108.1
|
L
H
8.8
108.1
|
L
H
8.8
108.1
|
| Onconetix Inc |
|
3.3
|
0.9
|
L
 1.1%
H
0.9
0.9
|
L
 8.4%
H
0.8
1.0
|
L
 -8.2%
H
0.7
1.0
|
L
 -76.3%
H
0.7
4.4
|
L
 -99.4%
H
0.7
209.5
|
L
 -100.0%
H
0.7
170018.8
|
L
 -100.0%
H
0.7
15453000
|
L
 -100.0%
H
0.7
15453000
|
| Talphera Inc |
|
73.2
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 10.2%
H
1.3
1.5
|
L
 3.7%
H
1.2
1.5
|
L
 56.7%
H
0.8
1.5
|
L
 243.9%
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| Telomir Pharma Inc |
|
80.5
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 -3.3%
H
1.1
1.3
|
L
 -7.9%
H
0.9
1.3
|
L
 -10%
H
0.9
1.4
|
L
 -25%
H
0.9
2.1
|
L
H
0.9
20.7
|
L
H
0.9
20.7
|
L
H
0.9
20.7
|
| Skye Bioscience Inc |
|
18.6
|
0.5
|
L
 1.9%
H
0.5
0.5
|
L
 -7.0%
H
0.3
0.6
|
L
 -24.3%
H
0.3
0.7
|
L
 -38.4%
H
0.3
0.9
|
L
 -84.9%
H
0.3
5.0
|
L
H
0.3
7.2
|
L
H
0.3
7.2
|
L
H
0.3
7.2
|
| Alumis Inc |
|
3,509.9
|
27.5
|
L
 -0.3%
H
27
27.9
|
L
 -2.6%
H
25.3
28.6
|
L
 -9.1%
H
25.3
30.2
|
L
 16.4%
H
18.4
31.4
|
L
 540.2%
H
3.8
31.4
|
L
H
2.8
31.4
|
L
H
2.8
31.4
|
L
H
2.8
31.4
|
| Actuate Therapeutics Inc |
|
24.4
|
1.0
|
L
 -7.3%
H
1
1.1
|
L
 -8.1%
H
1
1.3
|
L
 -17.1%
H
1
2.0
|
L
 -69.1%
H
1
3.4
|
L
 -87.3%
H
1
9.2
|
L
H
1
12.0
|
L
H
1
12.0
|
L
H
1
12.0
|
| Bicara Therapeutics Inc |
|
1,822.0
|
27.7
|
L
 -1.2%
H
27.1
28.4
|
L
 2.3%
H
25.3
28.4
|
L
 -6.6%
H
25.3
29.8
|
L
 22.8%
H
18.6
31.0
|
L
 171.9%
H
9.6
31.0
|
L
H
7.8
31.0
|
L
H
7.8
31.0
|
L
H
7.8
31.0
|
| Gelteq Ltd |
|
6.2
|
0.6
|
L
 3.6%
H
0.6
0.6
|
L
 11.5%
H
0.5
0.6
|
L
 7.4%
H
0.4
0.9
|
L
 23.4%
H
0.4
2.0
|
L
 -65.1%
H
0.4
2.0
|
L
H
0.4
5.5
|
L
H
0.4
5.5
|
L
H
0.4
5.5
|
| Atlantic Intl Corp |
|
56.9
|
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
 -2.8%
H
0.6
0.8
|
L
 -23.9%
H
0.6
1.0
|
L
 -53.3%
H
0.4
1.8
|
L
 -63.4%
H
0.4
5.3
|
L
 -73.1%
H
0.4
5.3
|
L
 -73.1%
H
0.4
5.3
|
L
 -73.1%
H
0.4
5.3
|
| BeiGene Ltd (ADR) |
|
40,610.9
|
359
|
L
 3.1%
H
349.9
361.3
|
L
 13.6%
H
309.9
361.3
|
L
 18.6%
H
295.4
361.3
|
L
 15.0%
H
254.0
361.3
|
L
 24.6%
H
254.0
385.2
|
L
 94.4%
H
172.7
385.2
|
L
 94.4%
H
172.7
385.2
|
L
 94.4%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
4.1
|
5.3
|
L
 4.1%
H
5.3
5.8
|
L
 5800%
H
0.1
5.8
|
L
 2555%
H
0.1
5.8
|
L
 1509.1%
H
0.1
5.8
|
L
 338.8%
H
0.1
5.8
|
L
 815.5%
H
0.1
5.8
|
L
 815.5%
H
0.1
5.8
|
L
 815.5%
H
0.1
5.8
|
| Ascentage Pharma Grp Intl (ADR) |
|
1,760.3
|
18.9
|
L
 -0.6%
H
18.7
18.9
|
L
 8.3%
H
16.6
19.0
|
L
 -0.2%
H
16.6
20.4
|
L
 -12.3%
H
16.4
22.6
|
L
 -55.0%
H
16.4
48.5
|
L
 8.5%
H
16.4
48.5
|
L
 8.5%
H
16.4
48.5
|
L
 8.5%
H
16.4
48.5
|
| Maze Therapeutics Inc |
|
1,509.8
|
27.3
|
L
 -4.8%
H
26.4
28.9
|
L
 1.3%
H
25.9
29
|
L
 -15.9%
H
25.9
32.7
|
L
 4.8%
H
22.7
33.5
|
L
 107.6%
H
12.8
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
| Aardvark Therapeutics Inc |
|
165.4
|
7.6
|
L
 -4.3%
H
7.3
7.8
|
L
 14.6%
H
6.6
8.1
|
L
 51.2%
H
5.0
8.1
|
L
 39.0%
H
3.4
8.1
|
L
 -37.0%
H
3.4
17.9
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
8.2
|
3.0
|
L
 -8.4%
H
3.0
3.2
|
L
 4.1%
H
2.7
3.6
|
L
 -42.5%
H
2.5
5.8
|
L
 35.7%
H
1.8
14.8
|
L
 -95.4%
H
1.8
76
|
L
H
1.8
76
|
L
H
1.8
76
|
L
H
1.8
76
|
| Jyong Biotech Ltd |
|
155.9
|
2.1
|
L
 3.5%
H
2
2.1
|
L
 -2.3%
H
1.9
2.2
|
L
 -8.7%
H
1.9
2.8
|
L
 2.4%
H
1.5
2.8
|
L
 -95.4%
H
1.4
67
|
L
 -79.2%
H
1.4
67
|
L
 -79.2%
H
1.4
67
|
L
 -79.2%
H
1.4
67
|
| LB Pharmaceuticals Inc |
|
1,314.8
|
45.9
|
L
 -4.5%
H
43.9
48.9
|
L
 14.4%
H
39.0
49.1
|
L
 35.9%
H
29.4
49.1
|
L
 43.4%
H
26.4
49.1
|
L
 165.0%
H
13.4
49.1
|
L
 165.0%
H
13.4
49.1
|
L
 165.0%
H
13.4
49.1
|
L
 165.0%
H
13.4
49.1
|
| Black Titan Corp |
|
8.6
|
0.8
|
L
H
0.8
0.8
|
L
 15.9%
H
0.7
0.9
|
L
H
0.6
1.1
|
L
 -42.5%
H
0.6
1.4
|
L
 -96.7%
H
0.6
23.5
|
L
 -96.7%
H
0.6
23.5
|
L
 -96.7%
H
0.6
23.5
|
L
 -96.7%
H
0.6
23.5
|
| Turn Therapeutics Inc |
|
286.0
|
9.6
|
L
 -7.8%
H
9.6
10.5
|
L
 14.8%
H
8.4
10.6
|
L
 9.0%
H
7.2
10.6
|
L
 153.3%
H
3.7
11.7
|
L
 37.1%
H
2.6
26.5
|
L
 37.1%
H
2.6
26.5
|
L
 37.1%
H
2.6
26.5
|
L
 37.1%
H
2.6
26.5
|
| MapLight Therapeutics Inc |
|
552.3
|
12.2
|
L
 0.1%
H
10.8
12.5
|
L
 -6.5%
H
10.8
13.7
|
L
 -69.4%
H
9.1
40.4
|
L
 -55.6%
H
9.1
40.4
|
L
 -33.6%
H
9.1
40.4
|
L
 -33.6%
H
9.1
40.4
|
L
 -33.6%
H
9.1
40.4
|
L
 -33.6%
H
9.1
40.4
|
| NovaBridge Biosciences ADR |
|
204.7
|
1.8
|
L
 1.1%
H
1.7
1.8
|
L
 10.6%
H
1.6
1.8
|
L
 -4.8%
H
1.6
2.0
|
L
 -19.6%
H
1.5
2.3
|
L
 -61.1%
H
1.5
5.2
|
L
 -61.1%
H
1.5
5.2
|
L
 -61.1%
H
1.5
5.2
|
L
 -61.1%
H
1.5
5.2
|
| Evommune Inc |
|
510.6
|
14.1
|
L
 -0.1%
H
13.6
14.3
|
L
 25.1%
H
10.9
14.4
|
L
 4.2%
H
10.5
14.4
|
L
 -38.6%
H
10.5
25.9
|
L
 -30.5%
H
10.5
33.2
|
L
 -30.4%
H
10.5
33.2
|
L
 -30.4%
H
10.5
33.2
|
L
 -30.4%
H
10.5
33.2
|
| Aktis Oncology Inc |
|
-
|
24.1
|
L
 -0.1%
H
23.8
25.3
|
L
 9.2%
H
21.5
25.3
|
L
 -15.2%
H
21.3
28.6
|
L
 29.6%
H
17.9
34.2
|
L
 7.6%
H
14.7
34.2
|
L
 7.6%
H
14.7
34.2
|
L
 7.6%
H
14.7
34.2
|
L
 7.6%
H
14.7
34.2
|
| Helus Pharma Inc |
|
620.5
|
10.0
|
L
 -13.8%
H
9.8
11.6
|
L
 28.0%
H
7.5
11.6
|
L
 51.0%
H
6.4
11.6
|
L
 88.5%
H
3.8
11.6
|
L
 32.9%
H
3.8
11.6
|
L
 32.9%
H
3.8
11.6
|
L
 32.9%
H
3.8
11.6
|
L
 32.9%
H
3.8
11.6
|
| NervGen Pharma Corp |
|
180.9
|
1.7
|
L
 -0.6%
H
1.7
1.7
|
L
 4.9%
H
1.6
1.8
|
L
 -8.6%
H
1.6
2.1
|
L
 -54.7%
H
1.6
4
|
L
 -70.4%
H
1.6
5.9
|
L
 -70.4%
H
1.6
5.9
|
L
 -70.4%
H
1.6
5.9
|
L
 -70.4%
H
1.6
5.9
|
| Veradermics Inc |
|
4,627.0
|
110.8
|
L
 -3.2%
H
107.7
113.9
|
L
 5.5%
H
93.8
114.4
|
L
 -11.3%
H
93.8
129.8
|
L
 4.3%
H
86.8
131.2
|
L
 193.4%
H
35.1
131.2
|
L
 193.4%
H
35.1
131.2
|
L
 193.4%
H
35.1
131.2
|
L
 193.4%
H
35.1
131.2
|
| Eikon Therapeutics Inc |
|
526.8
|
9.7
|
L
 4.7%
H
9.3
9.8
|
L
 5.7%
H
9.1
10
|
L
 -13.3%
H
8.7
11.3
|
L
 -2.3%
H
8.0
13.5
|
L
 -35.1%
H
7.9
16.5
|
L
 -35.1%
H
7.9
16.5
|
L
 -35.1%
H
7.9
16.5
|
L
 -35.1%
H
7.9
16.5
|
| Satellos Bioscience Inc |
|
208.5
|
10.0
|
L
 -0.2%
H
9.6
10.1
|
L
 0.2%
H
9.3
10.4
|
L
 6.0%
H
8.1
10.7
|
L
 30.2%
H
5.4
10.7
|
L
 -11.0%
H
5.4
13.4
|
L
 -11.0%
H
5.4
13.4
|
L
 -11.0%
H
5.4
13.4
|
L
 -11.0%
H
5.4
13.4
|
| Avalyn Pharma Inc |
|
1,532.2
|
34.6
|
L
 1.9%
H
32.8
35.2
|
L
 20.0%
H
27.6
35.2
|
L
 19.5%
H
24.9
35.2
|
L
 26.5%
H
24.2
35.2
|
L
 17.2%
H
24.2
35.2
|
L
 17.2%
H
24.2
35.2
|
L
 17.2%
H
24.2
35.2
|
L
 17.2%
H
24.2
35.2
|
| Seaport Therapeutics Inc |
|
1,232.3
|
23.0
|
L
 -2.5%
H
22.8
24.2
|
L
 12.5%
H
19.5
24.5
|
L
 12.2%
H
19.1
24.5
|
L
 43.4%
H
14.9
24.5
|
L
 16.0%
H
14.9
24.5
|
L
 16.0%
H
14.9
24.5
|
L
 16.0%
H
14.9
24.5
|
L
 16.0%
H
14.9
24.5
|
| Palatin Technologies Inc |
|
-
|
7.4
|
L
 -5.3%
H
7.3
8.2
|
L
 -4.4%
H
7.3
8.5
|
L
 -29.8%
H
7.2
10.3
|
L
 -48.0%
H
7.2
14.8
|
L
 -48.0%
H
7.2
14.8
|
L
 -48.0%
H
7.2
14.8
|
L
 -48.0%
H
7.2
14.8
|
L
 -48.0%
H
7.2
14.8
|
| Parabilis Medicines Inc |
|
4,370.2
|
35.7
|
L
 2.1%
H
34.9
36.9
|
L
 5.2%
H
32.1
36.9
|
L
 17.7%
H
26.4
36.9
|
L
 13.1%
H
24.5
36.9
|
L
 13.1%
H
24.5
36.9
|
L
 13.1%
H
24.5
36.9
|
L
 13.1%
H
24.5
36.9
|
L
 13.1%
H
24.5
36.9
|
| Vicore Pharma Holding AB ADR |
|
335.3
|
11.9
|
L
 0.8%
H
11.9
12.1
|
L
 4.5%
H
11.3
12.1
|
L
 -13.6%
H
10.5
12.9
|
L
 -13.6%
H
10.5
12.9
|
L
 -13.6%
H
10.5
12.9
|
L
 -13.6%
H
10.5
12.9
|
L
 -13.6%
H
10.5
12.9
|
L
 -13.6%
H
10.5
12.9
|
| Clinuvel Pharmaceuticals |
|
-
|
6.7
|
L
 0.9%
H
6.7
6.7
|
L
 3.9%
H
6.2
7.0
|
L
 -3.0%
H
6.2
7.9
|
L
 -3.0%
H
6.2
7.9
|
L
 -3.0%
H
6.2
7.9
|
L
 -3.0%
H
6.2
7.9
|
L
 -3.0%
H
6.2
7.9
|
L
 -3.0%
H
6.2
7.9
|
| Obsidian Therapeutics Inc |
|
-
|
35
|
L
 27.3%
H
28.5
37.2
|
L
 2.9%
H
23
37.2
|
L
 2.9%
H
23
37.2
|
L
 2.9%
H
23
37.2
|
L
 2.9%
H
23
37.2
|
L
 2.9%
H
23
37.2
|
L
 2.9%
H
23
37.2
|
L
 2.9%
H
23
37.2
|